1
|
Han MW, Suh CH, Kim PH, Kim S, Kim AY, Do KH, Lee JH, Gwon DI, Jung AY, Lee CW. Changing Gadolinium-Based Contrast Agents to Prevent Recurrent Acute Adverse Drug Reactions: 6-Year Cohort Study Using Propensity Score Matching. Korean J Radiol 2024; 25:824-832. [PMID: 39197827 PMCID: PMC11361800 DOI: 10.3348/kjr.2024.0248] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2023] [Revised: 06/05/2024] [Accepted: 07/04/2024] [Indexed: 09/01/2024] Open
Abstract
OBJECTIVE To determine the preventive effect of changing gadolinium-based contrast agents (GBCAs) to reduce the recurrence of GBCA-associated acute adverse drug reactions (ADRs). MATERIALS AND METHODS This retrospective, observational, single-center study-conducted between January 2016 and December 2021-included 238743 consecutive GBCA-enhanced MRI examinations. We focused on a subgroup of patients who experienced acute GBCA-associated ADRs during any of these examinations and subsequently underwent follow-up GBCA-enhanced MRI examinations up until July 2023. The follow-up examinations involved either the same (non-change group) or different (change group) GBCAs compared to the ones that initially caused the acute ADR. Baseline participant characteristics, generic profile of the GBCAs, administration of premedication, history of prior ADR to iodinated contrast media, and symptoms of GBCA-associated acute ADRs were retrospectively analyzed. Multivariable logistic regression with generalized estimating equations and propensity score matching were used. RESULTS A total of 1042 instances of acute ADRs (0.44%; 95% confidence interval [CI]: 0.41%-0.46%) were reported. Three-hundred and seventy-three patients underwent GBCA-enhanced MRI examinations after experiencing GBCA-associated acute ADRs within the study period; 31.9% (119/373) reexperienced acute ADRs at any of the follow-up examinations. The ADR recurrence was significantly lower in the GBCA change group than in the non-change group according to multivariable logistic regression (adjusted odds ratio [OR]: 0.35; 95% CI: 0.13-0.90; P = 0.03) and analysis with propensity score matching (14.3% [6/42] vs. 36.9% [31/84], respectively; OR: 0.32, 95% CI: 0.11-0.94; P = 0.04). A history of an ADR to iodinated contrast media (OR: 1.14, 95% CI: 0.68-1.90; P = 0.62) and premedication (adjusted OR: 2.09, 95% CI: 0.93-4.68; P = 0.07) were not significantly associated with GBCA-associated acute ADR recurrence. A separate analysis for recurrent allergic-like hypersensitivity reactions demonstrated similar results (adjusted OR: 0.20, 95% CI: 0.06-0.65; P < 0.01). CONCLUSION Changing GBCAs may reduce the risk of GBCA-associated acute ADR recurrence.
Collapse
Affiliation(s)
- Min Woo Han
- University of Ulsan College of Medicine, Seoul, Republic of Korea
| | - Chong Hyun Suh
- Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea
| | - Pyeong Hwa Kim
- Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea
| | - Seonok Kim
- Department of Clinical Epidemiology and Biostatistics, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea
| | - Ah Young Kim
- Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea
| | - Kyung-Hyun Do
- Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea
| | - Jeong Hyun Lee
- Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea
| | - Dong-Il Gwon
- Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea
| | - Ah Young Jung
- Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea
| | - Choong Wook Lee
- Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
| |
Collapse
|
2
|
Liu Y, Jia X, Zhao J, Peng Y, Yao X, Hu X, Cui J, Chen H, Chen X, Wu J, Hong N, Wang S, Wang Y. A Machine Learning-Based Unenhanced Radiomics Approach to Distinguishing Between Benign and Malignant Breast Lesions Using T2-Weighted and Diffusion-Weighted MRI. J Magn Reson Imaging 2024; 60:600-612. [PMID: 37933890 DOI: 10.1002/jmri.29111] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2023] [Revised: 10/17/2023] [Accepted: 10/17/2023] [Indexed: 11/08/2023] Open
Abstract
BACKGROUND Breast MRI has been recommended as supplemental screening tool to mammography and breast ultrasound of breast cancer by international guidelines, but its long examination time and use of contrast material remains concerning. PURPOSE To develop an unenhanced radiomics model with using non-gadolinium based sequences for detecting breast cancer based on T2-weighted (T2W) and diffusion-weighted (DW) MRI. STUDY TYPE Retrospective analysis followed by retrospective and prospective cohorts study. POPULATION 1760 patients: Of these, 1293 for model construction (n = 775 for training and 518 for validation). The remaining patients for model testing in internal retrospective (n = 167), internal prospective (n = 188), and external retrospective (n = 112) cohorts. FIELD STRENGTH/SEQUENCE 3.0T MR scanners from two institution. T2WI, DWI, and first contrast-enhanced T1-weighted sequence. ASSESSMENT AUCs in distinguishing breast cancer were compared between combined model with gadolinium agent sequence and unenhanced model. Subsequently, the AUCs in testing cohorts of unenhanced model was compared with two radiologists' diagnosis for this research. Finally, patient subgroup analysis in testing cohorts was performed based on clinical subgroups and different types of malignancies. STATISTICAL TESTS Mann-Whitney U test, Kruskal-Wallis H test, chi-square test, weighted kappa test, and DeLong's test. RESULTS The unenhanced radiomics model performed best under Gaussian process (GP) classifiers (AUC: training, 0.893; validation, 0.848) compared to support vector machine (SVM) and logistic, showing favorable prediction in testing cohorts (AUCs, 0.818-0.840). The AUCs for the unenhanced radiomics model were not statistically different in five cohorts from those of the combined radiomics model (P, 0.317-0.816), as well as the two radiologists (P, 0.181-0.918). The unenhanced radiomics model was least successful in identifying ductal carcinoma in situ, whereas did not show statistical significance in other subgroups. DATA CONCLUSION An unenhanced radiomics model based on T2WI and DWI has comparable diagnostic accuracy to the combined model using the gadolinium agent. LEVEL OF EVIDENCE 4 TECHNICAL EFFICACY: Stage 2.
Collapse
Affiliation(s)
- Yulu Liu
- Department of Radiology, Peking University People's Hospital, Beijing, China
| | - Xiaoxuan Jia
- Department of Radiology, Peking University People's Hospital, Beijing, China
| | - Jiaqi Zhao
- Department of Radiology, Jiangmen Central Hospital, Jiangmen, China
| | - Yuan Peng
- Department of Breast Surgery, Peking University People's Hospital, Beijing, China
| | - Xun Yao
- Department of Radiology, Peking University People's Hospital, Beijing, China
| | - Xuege Hu
- Department of Breast Surgery, Peking University People's Hospital, Beijing, China
| | - Jingjing Cui
- Department of Research and Development, United Imaging Intelligence (Beijing) Co., Ltd., Beijing, China
| | - Haoquan Chen
- Department of Radiology, Peking University People's Hospital, Beijing, China
| | - Xiufeng Chen
- Department of General Surgery, Beijing Aerospace General Hospital, Beijing, China
| | - Jing Wu
- Department of Radiology, Peking University People's Hospital, Beijing, China
| | - Nan Hong
- Department of Radiology, Peking University People's Hospital, Beijing, China
| | - Shu Wang
- Department of Breast Surgery, Peking University People's Hospital, Beijing, China
| | - Yi Wang
- Department of Radiology, Peking University People's Hospital, Beijing, China
| |
Collapse
|
3
|
Yasaka K, Saigusa H, Abe O. Effects of Intravenous Infusion of Iodine Contrast Media on the Tracheal Diameter and Lung Volume Measured with Deep Learning-Based Algorithm. JOURNAL OF IMAGING INFORMATICS IN MEDICINE 2024; 37:1609-1617. [PMID: 38448759 PMCID: PMC11300755 DOI: 10.1007/s10278-024-01071-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/18/2023] [Revised: 02/06/2024] [Accepted: 02/22/2024] [Indexed: 03/08/2024]
Abstract
This study aimed to investigate the effects of intravenous injection of iodine contrast agent on the tracheal diameter and lung volume. In this retrospective study, a total of 221 patients (71.1 ± 12.4 years, 174 males) who underwent vascular dynamic CT examination including chest were included. Unenhanced, arterial phase, and delayed-phase images were scanned. The tracheal luminal diameters at the level of the thoracic inlet and both lung volumes were evaluated by a radiologist using a commercial software, which allows automatic airway and lung segmentation. The tracheal diameter and both lung volumes were compared between the unenhanced vs. arterial and delayed phase using a paired t-test. The Bonferroni correction was performed for multiple group comparisons. The tracheal diameter in the arterial phase (18.6 ± 2.4 mm) was statistically significantly smaller than those in the unenhanced CT (19.1 ± 2.5 mm) (p < 0.001). No statistically significant difference was found in the tracheal diameter between the delayed phase (19.0 ± 2.4 mm) and unenhanced CT (p = 0.077). Both lung volumes in the arterial phase were 4131 ± 1051 mL which was significantly smaller than those in the unenhanced CT (4332 ± 1076 mL) (p < 0.001). No statistically significant difference was found in both lung volumes between the delayed phase (4284 ± 1054 mL) and unenhanced CT (p = 0.068). In conclusion, intravenous infusion of iodine contrast agent transiently decreased the tracheal diameter and both lung volumes.
Collapse
Affiliation(s)
- Koichiro Yasaka
- Department of Radiology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
| | - Hiroyuki Saigusa
- Department of Radiology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan
| | - Osamu Abe
- Department of Radiology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan
| |
Collapse
|
4
|
Asch D, Callahan MJ, Thomas KL, Desai S, Pahade JK. Management of Severe Allergic-Like Contrast Media Reactions: Pitfalls and Strategies, From the AJR Special Series on Contrast Media. AJR Am J Roentgenol 2024; 223:e2330044. [PMID: 37818959 DOI: 10.2214/ajr.23.30044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/13/2023]
Abstract
Adverse reactions to contrast media, although uncommon, are often high-acuity events and potentially life-threatening. Nonetheless, these events are treatable, and radiologists may be called on to manage a contrast media reaction. However, because these events are infrequent, they are prone to management errors. This Special Series Review highlights common pitfalls and practical tips for the management of acute contrast media reactions in children and adults. Recognition of frequent management errors and implementation of the mitigation strategies presented can ameliorate risk and improve patient outcomes. These measures include proper training regarding reaction management and medication administration, the prompt use of intramuscular epinephrine autoinjectors whenever a severe allergic-like reaction is suspected, the use of visual aids for quick reference in the setting of a reaction, and the recognition of adverse events that are not allergic-like reactions, which commonly require only supportive care.
Collapse
Affiliation(s)
- Daniella Asch
- Department of Radiology & Biomedical Imaging, Yale School of Medicine, 789 Howard Ave, New Haven, CT 06519-1304
| | | | - Kerry L Thomas
- Department of Radiology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC
| | - Sagar Desai
- Department of Radiology & Biomedical Imaging, Yale School of Medicine, 789 Howard Ave, New Haven, CT 06519-1304
| | - Jay K Pahade
- Department of Radiology & Biomedical Imaging, Yale School of Medicine, 789 Howard Ave, New Haven, CT 06519-1304
| |
Collapse
|
5
|
Harada TL, Uematsu T, Nakashima K, Sugino T, Nishimura S, Takahashi K, Hayashi T, Tadokoro Y. Non-contrast-enhanced breast MRI for evaluation of tumor volume change after neoadjuvant chemotherapy. Eur J Radiol 2024; 177:111555. [PMID: 38880053 DOI: 10.1016/j.ejrad.2024.111555] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2024] [Revised: 05/06/2024] [Accepted: 06/05/2024] [Indexed: 06/18/2024]
Abstract
PURPOSE Three-dimensional contrast-enhanced magnetic resonance imaging (3D-Ce-MRI) is a most powerful tool for evaluation of neoadjuvant chemotherapy (NAC). However, the use of contrast agent is invasive, expensive, and time consuming, Thus, contrast agent-free imaging is preferable. We aimed to investigate the tumor volume change after NAC using maximum intensity projection diffusion-weighted image (MIP-DWI) and 3D-Ce-MRI. METHOD We finally enrolled 55 breast cancer patients who underwent NAC in 2018. All MRI analyses were performed using SYNAPSE VINCENT® medical imaging system (Fujifilm Medical, Tokyo, Japan). We evaluated the tumor volumes before, during, and after NAC. Tumor volume before NAC on 3D-Ce-MRI was termed Pre-CE and those during and after NAC were termed Post-CE. The observer raised the lower end of the window width until the tumor was clearly visible and then manually deleted the non-tumor tissues. A month thereafter, the same observer who was blinded to the 3D-Ce-MRI results randomly evaluated the tumor volumes (Pre-DWI and Post-DWI) using MIP-DWI with the same method. Tumor volume change between ΔCE (Pre-CE - Post-CE/Pre-CE) and ΔDWI (Pre-DWI - Post-DWI/Pre-DWI) and the processing time for both methods (Time-DWI and Time-CE) were compared. RESULTS We enrolled 55 patients. Spearman's rho between ΔDWI and ΔCE for pure mass lesions, and non-mass enhancement (NME) was 0.89 (p < 0.01), 0.63(p < 0.01) respectively. Time-DWI was significantly shorter than Time-CE (41.3 ± 21.2 and 199.5 ± 98.3 respectively, p < 0.01). CONCLUSIONS Non-contrast-enhanced Breast MRI enables appropriate and faster evaluation of tumor volume change after NAC than 3D-Ce-MRI especially for mass lesions.
Collapse
Affiliation(s)
- Taiyo L Harada
- Division of Breast Imaging and Breast Interventional Radiology, Shizuoka Cancer Center Hospital, Shizuoka 411-8777, Japan
| | - Takayoshi Uematsu
- Division of Breast Imaging and Breast Interventional Radiology, Shizuoka Cancer Center Hospital, Shizuoka 411-8777, Japan.
| | - Kazuaki Nakashima
- Division of Breast Imaging and Breast Interventional Radiology, Shizuoka Cancer Center Hospital, Shizuoka 411-8777, Japan
| | - Takashi Sugino
- Division of Pathology, Shizuoka Cancer Center Hospital, Shizuoka 411-8777, Japan
| | - Seiichirou Nishimura
- Division of Breast Surgery, Shizuoka Cancer Center Hospital, Shizuoka 411-8777, Japan
| | - Kaoru Takahashi
- Division of Breast Surgery, Shizuoka Cancer Center Hospital, Shizuoka 411-8777, Japan
| | - Tomomi Hayashi
- Division of Breast Surgery, Shizuoka Cancer Center Hospital, Shizuoka 411-8777, Japan
| | - Yukiko Tadokoro
- Division of Breast Surgery, Shizuoka Cancer Center Hospital, Shizuoka 411-8777, Japan
| |
Collapse
|
6
|
Fukushima Y, Ozaki D, Taketomi-Takahashi A, Hirasawa H, Ujita K, Suto T, Tsushima Y. Assessment of first-time and repeated acute adverse reactions to gadolinium-based contrast agents in MRI: A retrospective study. Eur J Radiol 2024; 176:111504. [PMID: 38761445 DOI: 10.1016/j.ejrad.2024.111504] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2024] [Revised: 05/01/2024] [Accepted: 05/12/2024] [Indexed: 05/20/2024]
Abstract
PURPOSE To identify gadolinium-based contrast agents (GBCAs)-related and patient-related risk factors for acute adverse reactions (AARs), and to examine the incidence and severity of repeated AARs. METHODS This study retrospectively evaluated all intravenous GBCA injections in MRI studies at a single institution from January 2012 to September 2019. First-time AARs in patients without a past history of AARs and risk factors were assessed using multivariable regression models with generalized estimating equations. For patients with a past history of AAR(s), we evaluated the incidence of repeated AARs using the Fisher's exact test, as well as the severity of these repeated AARs. RESULTS First-time AARs occurred in 129 of 41,827 GBCA injections (0.31 %; 0.70 % of 18,431 patients). With gadoterate meglumine as the reference, the odds ratio (OR) for allergic-like reactions to three GBCAs ranged from 3.27 to 8.03 (p = 0.012 to <0.001). For chemotoxic reactions, the OR was 3.75 (p = 0.001) for gadoteridol. Outpatients had a lower OR for chemotoxic reactions, while higher ORs were observed in head/neck and breast MRI (p < 0.05). The OR for age was 0.99 (p < 0.05). Patients with a past history of AAR(s) had a 3.6 % incidence of mild repeated AARs for all GBCA, significantly higher than the 0.31 % in first-time AARs (p < 0.001). No effectiveness was found for steroid premedication. CONCLUSION The occurrence of first-time AARs was related to the GBCA used and other factors. The incidence of repeated AARs was higher than first-time AARs, though all were mild in severity.
Collapse
Affiliation(s)
- Yasuhiro Fukushima
- Department of Applied Medical Imaging, Gunma University Graduate School of Medicine, 3-39-22 Showa, Maebashi, Gunma 371-8511, Japan.
| | - Daisuke Ozaki
- Department of Radiology, Gunma University Hospital, 3-39-15 Showa, Maebashi, Gunma 371-8511, Japan
| | - Ayako Taketomi-Takahashi
- Department of Diagnostic Radiology and Nuclear Medicine, Gunma University Graduate School of Medicine, 3-39-22 Showa, Maebashi, Gunma 371-8511, Japan
| | - Hiromi Hirasawa
- Department of Radiology, Gunma University Hospital, 3-39-15 Showa, Maebashi, Gunma 371-8511, Japan
| | - Koichi Ujita
- Department of Radiology, Gunma University Hospital, 3-39-15 Showa, Maebashi, Gunma 371-8511, Japan
| | - Takayuki Suto
- Department of Radiology, Gunma University Hospital, 3-39-15 Showa, Maebashi, Gunma 371-8511, Japan
| | - Yoshito Tsushima
- Department of Diagnostic Radiology and Nuclear Medicine, Gunma University Graduate School of Medicine, 3-39-22 Showa, Maebashi, Gunma 371-8511, Japan
| |
Collapse
|
7
|
Kim PH, Hwang JY, Choi YH, Yoon HM, Lee CW. Safety of Gadoxetate Disodium for Hepatobiliary MRI in Children and Adolescents. Radiology 2024; 311:e232462. [PMID: 38860893 DOI: 10.1148/radiol.232462] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/12/2024]
Abstract
Background Despite a proven role in the characterization of liver lesions, use of the gadolinium-based contrast agent (GBCA) gadoxetate disodium at MRI is limited in children due to a lack of comparative safety data. Purpose To evaluate the safety of the GBCA gadoxetate disodium (a linear ionic hepatobiliary contrast agent [HBA]) in children and adolescents, compared with extracellular contrast agents (ECA). Materials and Methods A retrospective analysis was conducted in children and adolescents aged 18 years or younger who underwent HBA-enhanced MRI at one of three tertiary hospitals from January 2010 to December 2022. The incidence of GBCA-associated acute adverse events was compared between MRI examinations with a HBA and those with ECA. Severity was categorized according to American College of Radiology guidelines (mild, moderate, or severe). (a) Propensity score matching using multivariable logistic regression models and (b) inverse probability of treatment weighting analysis based on nine covariates (age, sex, asthma, allergic rhinitis, chronic urticaria or atopy, food allergy, drug allergy, premedication, and history of GBCA-associated adverse events) were used for confounder adjustment. Results A total of 1629 MRI examinations (ECA, n = 1256; HBA, n = 373) in 1079 patients were included (mean age, 8.6 years ± 6.5; 566 girls). The per-examination incidence of GBCA-associated acute adverse events showed no evidence of a difference, with rates of 0.9% (11 of 1256 examinations) for ECA and 1.3% (five of 373 examinations) for HBA (odds ratio [OR], 1.55 [95% CI: 0.54, 4.46]; P = .42). Acute adverse events were all mild with ECA, whereas with HBA, they were mild for four patients and moderate for one patient. There was no evidence of a difference in the incidence of acute adverse events, even in propensity score matching (OR, 1.33 [95% CI: 0.30, 5.96]; P = .71) and inverse probability of treatment weighting analysis (OR, 0.84 [95% CI: 0.25, 2.86]; P = .78). Conclusion Gadoxetate disodium showed no difference in acute adverse events compared with ECA in children and adolescents, with further large-scale pediatric studies required to confirm its safety. © RSNA, 2024 Supplemental material is available for this article. See also the editorial by Otero in this issue.
Collapse
Affiliation(s)
- Pyeong Hwa Kim
- From the Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea (P.H.K., H.M.Y., C.W.L.); Department of Radiology, Seoul National University Hospital, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul 03080, Republic of Korea (J.Y.H., Y.H.C.); and Department of Radiology, Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, College of Medicine, Pusan National University, Yangsan, Republic of Korea (J.Y.H.)
| | - Jae-Yeon Hwang
- From the Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea (P.H.K., H.M.Y., C.W.L.); Department of Radiology, Seoul National University Hospital, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul 03080, Republic of Korea (J.Y.H., Y.H.C.); and Department of Radiology, Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, College of Medicine, Pusan National University, Yangsan, Republic of Korea (J.Y.H.)
| | - Young Hun Choi
- From the Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea (P.H.K., H.M.Y., C.W.L.); Department of Radiology, Seoul National University Hospital, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul 03080, Republic of Korea (J.Y.H., Y.H.C.); and Department of Radiology, Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, College of Medicine, Pusan National University, Yangsan, Republic of Korea (J.Y.H.)
| | - Hee Mang Yoon
- From the Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea (P.H.K., H.M.Y., C.W.L.); Department of Radiology, Seoul National University Hospital, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul 03080, Republic of Korea (J.Y.H., Y.H.C.); and Department of Radiology, Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, College of Medicine, Pusan National University, Yangsan, Republic of Korea (J.Y.H.)
| | - Choong Wook Lee
- From the Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea (P.H.K., H.M.Y., C.W.L.); Department of Radiology, Seoul National University Hospital, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul 03080, Republic of Korea (J.Y.H., Y.H.C.); and Department of Radiology, Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, College of Medicine, Pusan National University, Yangsan, Republic of Korea (J.Y.H.)
| |
Collapse
|
8
|
Samet JD, Alizai H, Chalian M, Costelloe C, Deshmukh S, Kalia V, Kamel S, Mhuircheartaigh JN, Saade J, Walker E, Wessell D, Fayad LM. Society of skeletal radiology position paper - recommendations for contrast use in musculoskeletal MRI: when is non-contrast imaging enough? Skeletal Radiol 2024; 53:99-115. [PMID: 37300709 DOI: 10.1007/s00256-023-04367-8] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/15/2023] [Revised: 05/01/2023] [Accepted: 05/17/2023] [Indexed: 06/12/2023]
Abstract
The following White Paper will discuss the appropriateness of gadolinium administration in MRI for musculoskeletal indications. Musculoskeletal radiologists should consider the potential risks involved and practice the judicious use of intravenous contrast, restricting administration to cases where there is demonstrable added value. Specific nuances of when contrast is or is not recommended are discussed in detail and listed in table format. Briefly, contrast is recommended for bone and soft tissue lesions. For infection, contrast is reserved for chronic or complex cases. In rheumatology, contrast is recommended for early detection but not for advanced arthritis. Contrast is not recommended for sports injuries, routine MRI neurography, implants/hardware, or spine imaging, but is helpful in complex and post-operative cases.
Collapse
Affiliation(s)
- Jonathan D Samet
- Ann & Robert H. Lurie Children's Hospital of Chicago, Feinberg School of Medicine, Northwestern University, Chicago, USA.
| | - Hamza Alizai
- CHOP Department of Radiology, Children's Hospital of Philadelphia, Philadelphia, USA
| | - Majid Chalian
- Department of Radiology, University of Washington, Seattle, USA
| | | | | | - Vivek Kalia
- Children's Scottish Rite Hospital, Dallas, USA
| | - Sarah Kamel
- Thomas Jefferson University Hospital, Philadelphia, USA
| | | | - Jimmy Saade
- Creighton University School of Medicine, Phoenix Regional Campus, Phoenix, USA
| | - Eric Walker
- Penn State Health Milton S Hershey Medical Center, Hershey, USA
| | - Daniel Wessell
- Mayo Clinic Jacksonville Campus: Mayo Clinic in Florida, Jacksonville, USA
| | - Laura M Fayad
- Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Medicine, Baltimore, USA.
| |
Collapse
|
9
|
Rehman I, Pang E, Harris AC, Chang SD. Bi-parametric prostate MRI with a recall system for contrast enhanced imaging: Improving accessibility while maintaining quality. Eur J Radiol 2023; 169:111186. [PMID: 37989069 DOI: 10.1016/j.ejrad.2023.111186] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2023] [Revised: 10/25/2023] [Accepted: 11/02/2023] [Indexed: 11/23/2023]
Abstract
PURPOSE To review the efficacy of a recall system for bi-parametric non-contrast prostate MRI (bp-MRI). METHODS A bi-parametric protocol was instituted in July 2020 for all patients who had a prostate MRI requested, excluding those after treatment of prostate cancer, patients with hip prosthesis or pacemaker, and those who lived out-of-town. The protocol consisted of tri-planar T2-weighted and diffusion weighted images (DWI) (b = 50, 800 s/mm2 for ADC map; b = 1,500 s/mm2 acquired separately) in accordance with the Prostate Imaging Reporting & Data system (PI-RADS) v2.1 guidelines. After interpretation of bp-MRI exams, patients with equivocal (PI-RADS 3) lesions in peripheral zone (PZ) or any technical limitations were recalled for contrast administration. RESULTS Out of 909 bp-MRI scans performed from July 2020 to April 2021, only 52 (5.7 %) were recalled, of which 46 (88.5 %) attended. Amongst these, 41/52 (78.8 %) were recalled for PZ PI-RADS 3 lesions, while the rest of 11 (21.2 %) cases were recalled for technical reasons. Mean time to subsequent recall scan was 11.6 days. On assessment of post-contrast imaging, 29/46 (63 %) cases were upgraded to PI-RADS 4 while 17/46 (37 %) remained PI-RADS 3. This system avoided contrast-agent use in 857 patients, with contrast cost savings of €64,620 (US$68,560) and 214 hours 15 minutes of scanner time was saved. This allowed 255 additional bp-MRI scans to be performed, reducing the waitlist from 1 year to 2-3 weeks. CONCLUSION A bi-parametric prostate MRI protocol with a robust recall system for contrast administration not only saved time eliminating the marked backlog but was also more cost efficient without compromising the quality of patient care.
Collapse
Affiliation(s)
- Iffat Rehman
- Department of Radiology, Vancouver General Hospital, University of British Columbia, 899 West 12(th) Avenue Vancouver, BC V5Z 1M9, Canada.
| | - Emily Pang
- Department of Radiology, Vancouver General Hospital, University of British Columbia, 899 West 12(th) Avenue Vancouver, BC V5Z 1M9, Canada
| | - Alison C Harris
- Department of Radiology, Vancouver General Hospital, University of British Columbia, 899 West 12(th) Avenue Vancouver, BC V5Z 1M9, Canada
| | - Silvia D Chang
- Department of Radiology, Vancouver General Hospital, University of British Columbia, 899 West 12(th) Avenue Vancouver, BC V5Z 1M9, Canada
| |
Collapse
|
10
|
Grolman E, Sirianni QEA, Dunmore-Buyze J, Cruje C, Drangova M, Gillies ER. Depolymerizing self-immolative polymeric lanthanide chelates for vascular imaging. Acta Biomater 2023; 169:530-541. [PMID: 37507034 DOI: 10.1016/j.actbio.2023.07.034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2023] [Revised: 07/03/2023] [Accepted: 07/22/2023] [Indexed: 07/30/2023]
Abstract
Medical imaging is widely used clinically and in research to understand disease progression and monitor responses to therapies. Vascular imaging enables the study of vascular disease and therapy, but exogenous contrast agents are generally needed to distinguish the vasculature from surrounding soft tissues. Lanthanide-based agents are commonly employed in MRI, but are also of growing interest for micro-CT, as the position of their k-edges allows them to provide enhanced contrast and also to be employed in dual-energy micro-CT, a technique that can distinguish contrast-enhanced blood vessels from tissues such as bone. Small molecule Gd3+ chelates are available, but are excreted too rapidly. At the same time, a lack of rapid clearance from the body for long-circulating agents presents toxicity concerns. To address these challenges, we describe here the use of self-immolative polymers for the development of new degradable chelates that depolymerize completely from end-to-end following the cleavage of a single end-cap from the polymer terminus. We demonstrate that tuning the end-cap allows the rate of depolymerization to be controlled, while tuning the polymer length enables the polymer to exhibit long circulation times in the blood of mice. After successfully providing one hour of blood contrast, depolymerization led to excretion of the resulting small molecule chelates into the bladder. Despite the high doses required for micro-CT, the agents were well tolerated in mice. Thus, these self-immolative polymeric chelates provide a new platform for the development of medical imaging contrast agents. STATEMENT OF SIGNIFICANCE: Vascular imaging is used clinically to diagnose and monitor vascular disease and in research to understand the progression of disease and study responses to new therapies. For techniques such as magnetic resonance imaging and x-ray computed tomography (CT), long circulating contrast agents are needed to differentiate the vasculature from surrounding tissues. However, if these agents are not rapidly excreted from the body, they can lead to toxicity. We present here a new polymeric system that can chelate hundreds of lanthanide ions for imaging contrast and can circulate for one hour in the blood, but then after end-cap cleavage breaks down completely into small molecules for excretion. The successful application of this system in micro-CT in mice is demonstrated.
Collapse
Affiliation(s)
- Eric Grolman
- School of Biomedical Engineering, The University of Western Ontario, 1151 Richmond Street, London, Ontario N6A 5B9, Canada; Robarts Research Institute, The University of Western Ontario, 1151 Richmond Street, London, Ontario N6A 5B7, Canada
| | - Quinton E A Sirianni
- Department of Chemistry, The University of Western Ontario, 1151 Richmond Street, London, Ontario N6A 5B7, Canada
| | - Joy Dunmore-Buyze
- Robarts Research Institute, The University of Western Ontario, 1151 Richmond Street, London, Ontario N6A 5B7, Canada
| | - Charmainne Cruje
- Department of Medical Biophysics, The University of Western Ontario, 1151 Richmond Street, London, Ontario N6A 5C1, Canada
| | - Maria Drangova
- School of Biomedical Engineering, The University of Western Ontario, 1151 Richmond Street, London, Ontario N6A 5B9, Canada; Robarts Research Institute, The University of Western Ontario, 1151 Richmond Street, London, Ontario N6A 5B7, Canada; Department of Medical Biophysics, The University of Western Ontario, 1151 Richmond Street, London, Ontario N6A 5C1, Canada.
| | - Elizabeth R Gillies
- School of Biomedical Engineering, The University of Western Ontario, 1151 Richmond Street, London, Ontario N6A 5B9, Canada; Department of Chemistry, The University of Western Ontario, 1151 Richmond Street, London, Ontario N6A 5B7, Canada; Department of Chemical and Biochemical Engineering, The University of Western Ontario, 1151 Richmond Street, London, Ontario N6A 5B9, Canada.
| |
Collapse
|
11
|
Mallio CA, Radbruch A, Deike-Hofmann K, van der Molen AJ, Dekkers IA, Zaharchuk G, Parizel PM, Beomonte Zobel B, Quattrocchi CC. Artificial Intelligence to Reduce or Eliminate the Need for Gadolinium-Based Contrast Agents in Brain and Cardiac MRI: A Literature Review. Invest Radiol 2023; 58:746-753. [PMID: 37126454 DOI: 10.1097/rli.0000000000000983] [Citation(s) in RCA: 9] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/02/2023]
Abstract
ABSTRACT Brain and cardiac MRIs are fundamental noninvasive imaging tools, which can provide important clinical information and can be performed without or with gadolinium-based contrast agents (GBCAs), depending on the clinical indication. It is currently a topic of debate whether it would be feasible to extract information such as standard gadolinium-enhanced MRI while injecting either less or no GBCAs. Artificial intelligence (AI) is a great source of innovation in medical imaging and has been explored as a method to synthesize virtual contrast MR images, potentially yielding similar diagnostic performance without the need to administer GBCAs. If possible, there would be significant benefits, including reduction of costs, acquisition time, and environmental impact with respect to conventional contrast-enhanced MRI examinations. Given its promise, we believe additional research is needed to increase the evidence to make these AI solutions feasible, reliable, and robust enough to be integrated into the clinical framework. Here, we review recent AI studies aimed at reducing or replacing gadolinium in brain and cardiac imaging while maintaining diagnostic image quality.
Collapse
Affiliation(s)
| | - Alexander Radbruch
- Clinic for Diagnostic and Interventional Neuroradiology, University Clinic Bonn, and German Center for Neurodegenerative Diseases, DZNE, Bonn, Germany
| | - Katerina Deike-Hofmann
- Clinic for Diagnostic and Interventional Neuroradiology, University Clinic Bonn, and German Center for Neurodegenerative Diseases, DZNE, Bonn, Germany
| | - Aart J van der Molen
- Department of Radiology, Leiden University Medical Center, Leiden, the Netherlands
| | - Ilona A Dekkers
- Department of Radiology, Leiden University Medical Center, Leiden, the Netherlands
| | - Greg Zaharchuk
- Department of Radiology, Stanford University, Stanford, CA
| | | | | | | |
Collapse
|
12
|
Le Q, Lee J, Ko S, Kim H, Vu TY, Choe YS, Oh Y, Shim G. Enzyme-responsive macrocyclic metal complexes for biomedical imaging. Bioeng Transl Med 2023; 8:e10478. [PMID: 37693046 PMCID: PMC10487310 DOI: 10.1002/btm2.10478] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2022] [Revised: 12/05/2022] [Accepted: 12/08/2022] [Indexed: 09/12/2023] Open
Abstract
Metal chelator-based contrast agents are used as tumor navigators for cancer diagnosis. Although approved metal chelators show excellent contrast performance in magnetic resonance imaging (MRI), large doses are required for cancer diagnoses due to rapid clearance and nonspecific accumulation throughout the body, which can compromise safety. The present study describes an enzyme-responsive metal delivery system, in which enzyme overexpressed in the tumor microenvironment selectively activates the tumor uptake of gadolinium (Gd). Gd was loaded into enzyme-responsive macrocyclam (ErMC) modified with a PEGylated enzyme-cleavable peptide resulting in Gd@ErMC. The PEGylated shell layer protected Gd@ErMC from nonspecific binding in the blood, increasing the half-life of the contrast agent. Specific cleavage of the PEGylated shell layer by the enzyme selectively liberated Gd from Gd@ErMC at the tumor site. Evaluation of the in vivo distribution of Gd@ErMC in tumor-bearing mice by MRI and positron emission tomography (PET) showed that Gd@ErMC had an extended half-life and was highly specific. Histological and serological analysis of Gd@ErMC-treated mice showed that this agent was safe. This novel enzyme-responsive contrast agent delivery system shows promise as specific theranostic agent for MR-guided radiotherapy.
Collapse
Affiliation(s)
- Quoc‐Viet Le
- Faculty of PharmacyTon Duc Thang UniversityHo Chi Minh CityVietnam
| | - Jaiwoo Lee
- College of Pharmacy and Research Institute of Pharmaceutical SciencesSeoul National UniversitySeoulRepublic of Korea
| | - Seungbeom Ko
- College of Pharmacy and Research Institute of Pharmaceutical SciencesSeoul National UniversitySeoulRepublic of Korea
| | - Hyunjung Kim
- Department of Nuclear Medicine, Samsung Medical CenterSungkyunkwan University School of MedicineSeoulRepublic of Korea
| | - Thien Y Vu
- Faculty of PharmacyTon Duc Thang UniversityHo Chi Minh CityVietnam
| | - Yearn Seong Choe
- Department of Nuclear Medicine, Samsung Medical CenterSungkyunkwan University School of MedicineSeoulRepublic of Korea
- Department of Health Sciences and Technology, SAIHSTSungkyunkwan UniversitySeoulRepublic of Korea
| | - Yu‐Kyoung Oh
- College of Pharmacy and Research Institute of Pharmaceutical SciencesSeoul National UniversitySeoulRepublic of Korea
| | - Gayong Shim
- School of Systems Biomedical Science and Integrative Institute of Basic SciencesSoongsil UniversitySeoulRepublic of Korea
| |
Collapse
|
13
|
Sáenz de Santa María R, Labella M, Bogas G, Doña I, Torres MJ. Hypersensitivity to gadolinium-based contrast. Curr Opin Allergy Clin Immunol 2023; 23:300-306. [PMID: 37357781 DOI: 10.1097/aci.0000000000000911] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/27/2023]
Abstract
PURPOSE OF REVIEW The use of contrast media is increasing in recent decades. Although gadolinium-based contrast agents (GBCAs) are generally well tolerated, adverse reactions, including hypersensitivity reactions (HSRs), although infrequent, may occur. It is important to perform a thorough allergological evaluation in patients with suspected GBCA-HSRs to avoid potentially serious reactions in subsequent exposures. RECENT FINDINGS Data on GBCA-HSRs are scarce. Most published articles dealing with skin tests and drug provocation tests (DPTs) with GBCAs are case series and small cohorts. Controversies exist about the role of premedication for preventing HSRs on subsequent exposures. Selection of well tolerated alternatives is based on potential cross-reactivity among GBCAs; however, the extent of cross-reactivity among them remains unclear. SUMMARY As premedication is not useful because breakthrough reactions are frequent in patients with GBCA-HSRs in subsequent exposures, an allergological evaluation is required. Available data suggest a high negative predictive value of skin tests, being crucial for guiding the selection of an alternative GBCA. However, DPTs are still necessary to confirm or exclude the diagnosis or find alternative GBCAs. Cross-reactivity is high among GBCAs belonging from the same group, mainly among macrocyclic compounds, so this must be taken into account for selecting alternatives.
Collapse
Affiliation(s)
- Rocío Sáenz de Santa María
- Allergy Unit, Hospital Regional Universitario de Málaga
- Allergy Research Group, Instituto de Investigación Biomédica de Málaga-IBIMA, Hospital Civil
| | - Marina Labella
- Allergy Unit, Hospital Regional Universitario de Málaga
- Allergy Research Group, Instituto de Investigación Biomédica de Málaga-IBIMA, Hospital Civil
| | - Gádor Bogas
- Allergy Unit, Hospital Regional Universitario de Málaga
- Allergy Research Group, Instituto de Investigación Biomédica de Málaga-IBIMA, Hospital Civil
| | - Inmaculada Doña
- Allergy Unit, Hospital Regional Universitario de Málaga
- Allergy Research Group, Instituto de Investigación Biomédica de Málaga-IBIMA, Hospital Civil
| | - María José Torres
- Allergy Unit, Hospital Regional Universitario de Málaga
- Allergy Research Group, Instituto de Investigación Biomédica de Málaga-IBIMA, Hospital Civil
- Nanostructures for Diagnosing and Treatment of Allergic Diseases Laboratory, Andalusian Center for Nanomedicine and Biotechnology-BIONAND, Parque Tecnológico de Andalucía
- Departamento de Medicina, Universidad de Málaga, Facultad de Medicina, Málaga, Spain
| |
Collapse
|
14
|
Takanezawa Y, Nakamura R, Ohshiro Y, Uraguchi S, Kiyono M. Gadolinium-based contrast agents suppress adipocyte differentiation in 3T3-L1 cells. Toxicol Lett 2023; 383:S0378-4274(23)00218-7. [PMID: 37437671 DOI: 10.1016/j.toxlet.2023.07.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2023] [Revised: 06/28/2023] [Accepted: 07/09/2023] [Indexed: 07/14/2023]
Abstract
Gadolinium-based contrast agents (GBCAs) are widely used in magnetic resonance imaging (MRI) to improve the sensitivity and enhance diagnostic performance. GBCAs are mostly eliminated from the body through the kidney after administration; however small amounts of gadolinium are retained in the brain and other tissues. Although there is increasing concern about the adverse health effects of gadolinium, the cellular effects of GBCAs remains poorly understood. Here, we elucidated the potential cytotoxicity of the GBCAs Omniscan and Gadovist in 12 different cell lines, especially 3T3-L1 adipocyte cell line. Omniscan and Gadovist treatments significantly increased intracellular gadolinium levels in 3T3-L1 cells in a time- and dose-dependent manner. Additionally, Omniscan and Gadovist treatments downregulated the expression of adipocyte differentiation markers, including peroxisome proliferator-activated receptor γ (PPARG), adiponectin (ADIPOQ), and fatty acid-binding protein (FABP4), in 3T3-L1 cells, especially during early differentiation (day 0-2). Moreover, histological analysis using Oil red O staining showed that gadolinium chloride (GdCl3) treatment suppressed lipid droplet accumulation and the expression of adipocyte differentiation markers. Overall, the results showed that Omniscan and Gadovist treatment suppressed adipocyte differentiation in 3T3-L1 cells, contributing to the understanding of the potential toxic effects of GBCA exposure.
Collapse
Affiliation(s)
- Yasukazu Takanezawa
- Department of Public Health, School of Pharmacy, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan
| | - Ryosuke Nakamura
- Department of Public Health, School of Pharmacy, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan
| | - Yuka Ohshiro
- Department of Public Health, School of Pharmacy, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan
| | - Shimpei Uraguchi
- Department of Public Health, School of Pharmacy, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan
| | - Masako Kiyono
- Department of Public Health, School of Pharmacy, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan.
| |
Collapse
|
15
|
Hwang KP, Elshafeey NA, Kotrotsou A, Chen H, Son JB, Boge M, Mohamed RM, Abdelhafez AH, Adrada BE, Panthi B, Sun J, Musall BC, Zhang S, Candelaria RP, White JB, Ravenberg EE, Tripathy D, Yam C, Litton JK, Huo L, Thompson AM, Wei P, Yang WT, Pagel MD, Ma J, Rauch GM. A Radiomics Model Based on Synthetic MRI Acquisition for Predicting Neoadjuvant Systemic Treatment Response in Triple-Negative Breast Cancer. Radiol Imaging Cancer 2023; 5:e230009. [PMID: 37505106 PMCID: PMC10413296 DOI: 10.1148/rycan.230009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2023] [Revised: 04/18/2023] [Accepted: 06/03/2023] [Indexed: 07/29/2023]
Abstract
Purpose To determine if a radiomics model based on quantitative maps acquired with synthetic MRI (SyMRI) is useful for predicting neoadjuvant systemic therapy (NAST) response in triple-negative breast cancer (TNBC). Materials and Methods In this prospective study, 181 women diagnosed with stage I-III TNBC were scanned with a SyMRI sequence at baseline and at midtreatment (after four cycles of NAST), producing T1, T2, and proton density (PD) maps. Histopathologic analysis at surgery was used to determine pathologic complete response (pCR) or non-pCR status. From three-dimensional tumor contours drawn on the three maps, 310 histogram and textural features were extracted, resulting in 930 features per scan. Radiomic features were compared between pCR and non-pCR groups by using Wilcoxon rank sum test. To build a multivariable predictive model, logistic regression with elastic net regularization and cross-validation was performed for texture feature selection using 119 participants (median age, 52 years [range, 26-77 years]). An independent testing cohort of 62 participants (median age, 48 years [range, 23-74 years]) was used to evaluate and compare the models by area under the receiver operating characteristic curve (AUC). Results Univariable analysis identified 15 T1, 10 T2, and 12 PD radiomic features at midtreatment that predicted pCR with an AUC greater than 0.70 in both the training and testing cohorts. Multivariable radiomics models of maps acquired at midtreatment demonstrated superior performance over those acquired at baseline, achieving AUCs as high as 0.78 and 0.72 in the training and testing cohorts, respectively. Conclusion SyMRI-based radiomic features acquired at midtreatment are potentially useful for identifying early NAST responders in TNBC. Keywords: MR Imaging, Breast, Outcomes Analysis ClinicalTrials.gov registration no. NCT02276443 Supplemental material is available for this article. © RSNA, 2023 See also the commentary by Houser and Rapelyea in this issue.
Collapse
Affiliation(s)
- Ken-Pin Hwang
- From the Departments of Imaging Physics (K.P.H., A.K., J.B.S., B.P.,
B.C.M., J.M.), Breast Imaging (N.A.E., M.B., R.M.M., A.H.A., B.E.A., R.P.C.,
W.T.Y., G.M.R.), Biostatistics (H.C., J.S., P.W.), Cancer Systems Imaging (S.Z.,
M.D.P.), Moon Shots Operations (J.B.W.), Breast Medical Oncology (E.E.R., D.T.,
C.Y.), Clinical Research (J.K.L.), Pathology (L.H.), and Abdominal Imaging
(G.M.R.), The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd,
Houston, TX 77030; and Division of Surgical Oncology, Baylor College of
Medicine, Houston, Tex (A.M.T.)
| | - Nabil A. Elshafeey
- From the Departments of Imaging Physics (K.P.H., A.K., J.B.S., B.P.,
B.C.M., J.M.), Breast Imaging (N.A.E., M.B., R.M.M., A.H.A., B.E.A., R.P.C.,
W.T.Y., G.M.R.), Biostatistics (H.C., J.S., P.W.), Cancer Systems Imaging (S.Z.,
M.D.P.), Moon Shots Operations (J.B.W.), Breast Medical Oncology (E.E.R., D.T.,
C.Y.), Clinical Research (J.K.L.), Pathology (L.H.), and Abdominal Imaging
(G.M.R.), The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd,
Houston, TX 77030; and Division of Surgical Oncology, Baylor College of
Medicine, Houston, Tex (A.M.T.)
| | - Aikaterini Kotrotsou
- From the Departments of Imaging Physics (K.P.H., A.K., J.B.S., B.P.,
B.C.M., J.M.), Breast Imaging (N.A.E., M.B., R.M.M., A.H.A., B.E.A., R.P.C.,
W.T.Y., G.M.R.), Biostatistics (H.C., J.S., P.W.), Cancer Systems Imaging (S.Z.,
M.D.P.), Moon Shots Operations (J.B.W.), Breast Medical Oncology (E.E.R., D.T.,
C.Y.), Clinical Research (J.K.L.), Pathology (L.H.), and Abdominal Imaging
(G.M.R.), The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd,
Houston, TX 77030; and Division of Surgical Oncology, Baylor College of
Medicine, Houston, Tex (A.M.T.)
| | - Huiqin Chen
- From the Departments of Imaging Physics (K.P.H., A.K., J.B.S., B.P.,
B.C.M., J.M.), Breast Imaging (N.A.E., M.B., R.M.M., A.H.A., B.E.A., R.P.C.,
W.T.Y., G.M.R.), Biostatistics (H.C., J.S., P.W.), Cancer Systems Imaging (S.Z.,
M.D.P.), Moon Shots Operations (J.B.W.), Breast Medical Oncology (E.E.R., D.T.,
C.Y.), Clinical Research (J.K.L.), Pathology (L.H.), and Abdominal Imaging
(G.M.R.), The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd,
Houston, TX 77030; and Division of Surgical Oncology, Baylor College of
Medicine, Houston, Tex (A.M.T.)
| | - Jong Bum Son
- From the Departments of Imaging Physics (K.P.H., A.K., J.B.S., B.P.,
B.C.M., J.M.), Breast Imaging (N.A.E., M.B., R.M.M., A.H.A., B.E.A., R.P.C.,
W.T.Y., G.M.R.), Biostatistics (H.C., J.S., P.W.), Cancer Systems Imaging (S.Z.,
M.D.P.), Moon Shots Operations (J.B.W.), Breast Medical Oncology (E.E.R., D.T.,
C.Y.), Clinical Research (J.K.L.), Pathology (L.H.), and Abdominal Imaging
(G.M.R.), The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd,
Houston, TX 77030; and Division of Surgical Oncology, Baylor College of
Medicine, Houston, Tex (A.M.T.)
| | - Medine Boge
- From the Departments of Imaging Physics (K.P.H., A.K., J.B.S., B.P.,
B.C.M., J.M.), Breast Imaging (N.A.E., M.B., R.M.M., A.H.A., B.E.A., R.P.C.,
W.T.Y., G.M.R.), Biostatistics (H.C., J.S., P.W.), Cancer Systems Imaging (S.Z.,
M.D.P.), Moon Shots Operations (J.B.W.), Breast Medical Oncology (E.E.R., D.T.,
C.Y.), Clinical Research (J.K.L.), Pathology (L.H.), and Abdominal Imaging
(G.M.R.), The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd,
Houston, TX 77030; and Division of Surgical Oncology, Baylor College of
Medicine, Houston, Tex (A.M.T.)
| | - Rania M. Mohamed
- From the Departments of Imaging Physics (K.P.H., A.K., J.B.S., B.P.,
B.C.M., J.M.), Breast Imaging (N.A.E., M.B., R.M.M., A.H.A., B.E.A., R.P.C.,
W.T.Y., G.M.R.), Biostatistics (H.C., J.S., P.W.), Cancer Systems Imaging (S.Z.,
M.D.P.), Moon Shots Operations (J.B.W.), Breast Medical Oncology (E.E.R., D.T.,
C.Y.), Clinical Research (J.K.L.), Pathology (L.H.), and Abdominal Imaging
(G.M.R.), The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd,
Houston, TX 77030; and Division of Surgical Oncology, Baylor College of
Medicine, Houston, Tex (A.M.T.)
| | - Abeer H. Abdelhafez
- From the Departments of Imaging Physics (K.P.H., A.K., J.B.S., B.P.,
B.C.M., J.M.), Breast Imaging (N.A.E., M.B., R.M.M., A.H.A., B.E.A., R.P.C.,
W.T.Y., G.M.R.), Biostatistics (H.C., J.S., P.W.), Cancer Systems Imaging (S.Z.,
M.D.P.), Moon Shots Operations (J.B.W.), Breast Medical Oncology (E.E.R., D.T.,
C.Y.), Clinical Research (J.K.L.), Pathology (L.H.), and Abdominal Imaging
(G.M.R.), The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd,
Houston, TX 77030; and Division of Surgical Oncology, Baylor College of
Medicine, Houston, Tex (A.M.T.)
| | - Beatriz E. Adrada
- From the Departments of Imaging Physics (K.P.H., A.K., J.B.S., B.P.,
B.C.M., J.M.), Breast Imaging (N.A.E., M.B., R.M.M., A.H.A., B.E.A., R.P.C.,
W.T.Y., G.M.R.), Biostatistics (H.C., J.S., P.W.), Cancer Systems Imaging (S.Z.,
M.D.P.), Moon Shots Operations (J.B.W.), Breast Medical Oncology (E.E.R., D.T.,
C.Y.), Clinical Research (J.K.L.), Pathology (L.H.), and Abdominal Imaging
(G.M.R.), The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd,
Houston, TX 77030; and Division of Surgical Oncology, Baylor College of
Medicine, Houston, Tex (A.M.T.)
| | - Bikash Panthi
- From the Departments of Imaging Physics (K.P.H., A.K., J.B.S., B.P.,
B.C.M., J.M.), Breast Imaging (N.A.E., M.B., R.M.M., A.H.A., B.E.A., R.P.C.,
W.T.Y., G.M.R.), Biostatistics (H.C., J.S., P.W.), Cancer Systems Imaging (S.Z.,
M.D.P.), Moon Shots Operations (J.B.W.), Breast Medical Oncology (E.E.R., D.T.,
C.Y.), Clinical Research (J.K.L.), Pathology (L.H.), and Abdominal Imaging
(G.M.R.), The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd,
Houston, TX 77030; and Division of Surgical Oncology, Baylor College of
Medicine, Houston, Tex (A.M.T.)
| | - Jia Sun
- From the Departments of Imaging Physics (K.P.H., A.K., J.B.S., B.P.,
B.C.M., J.M.), Breast Imaging (N.A.E., M.B., R.M.M., A.H.A., B.E.A., R.P.C.,
W.T.Y., G.M.R.), Biostatistics (H.C., J.S., P.W.), Cancer Systems Imaging (S.Z.,
M.D.P.), Moon Shots Operations (J.B.W.), Breast Medical Oncology (E.E.R., D.T.,
C.Y.), Clinical Research (J.K.L.), Pathology (L.H.), and Abdominal Imaging
(G.M.R.), The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd,
Houston, TX 77030; and Division of Surgical Oncology, Baylor College of
Medicine, Houston, Tex (A.M.T.)
| | - Benjamin C. Musall
- From the Departments of Imaging Physics (K.P.H., A.K., J.B.S., B.P.,
B.C.M., J.M.), Breast Imaging (N.A.E., M.B., R.M.M., A.H.A., B.E.A., R.P.C.,
W.T.Y., G.M.R.), Biostatistics (H.C., J.S., P.W.), Cancer Systems Imaging (S.Z.,
M.D.P.), Moon Shots Operations (J.B.W.), Breast Medical Oncology (E.E.R., D.T.,
C.Y.), Clinical Research (J.K.L.), Pathology (L.H.), and Abdominal Imaging
(G.M.R.), The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd,
Houston, TX 77030; and Division of Surgical Oncology, Baylor College of
Medicine, Houston, Tex (A.M.T.)
| | - Shu Zhang
- From the Departments of Imaging Physics (K.P.H., A.K., J.B.S., B.P.,
B.C.M., J.M.), Breast Imaging (N.A.E., M.B., R.M.M., A.H.A., B.E.A., R.P.C.,
W.T.Y., G.M.R.), Biostatistics (H.C., J.S., P.W.), Cancer Systems Imaging (S.Z.,
M.D.P.), Moon Shots Operations (J.B.W.), Breast Medical Oncology (E.E.R., D.T.,
C.Y.), Clinical Research (J.K.L.), Pathology (L.H.), and Abdominal Imaging
(G.M.R.), The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd,
Houston, TX 77030; and Division of Surgical Oncology, Baylor College of
Medicine, Houston, Tex (A.M.T.)
| | - Rosalind P. Candelaria
- From the Departments of Imaging Physics (K.P.H., A.K., J.B.S., B.P.,
B.C.M., J.M.), Breast Imaging (N.A.E., M.B., R.M.M., A.H.A., B.E.A., R.P.C.,
W.T.Y., G.M.R.), Biostatistics (H.C., J.S., P.W.), Cancer Systems Imaging (S.Z.,
M.D.P.), Moon Shots Operations (J.B.W.), Breast Medical Oncology (E.E.R., D.T.,
C.Y.), Clinical Research (J.K.L.), Pathology (L.H.), and Abdominal Imaging
(G.M.R.), The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd,
Houston, TX 77030; and Division of Surgical Oncology, Baylor College of
Medicine, Houston, Tex (A.M.T.)
| | - Jason B. White
- From the Departments of Imaging Physics (K.P.H., A.K., J.B.S., B.P.,
B.C.M., J.M.), Breast Imaging (N.A.E., M.B., R.M.M., A.H.A., B.E.A., R.P.C.,
W.T.Y., G.M.R.), Biostatistics (H.C., J.S., P.W.), Cancer Systems Imaging (S.Z.,
M.D.P.), Moon Shots Operations (J.B.W.), Breast Medical Oncology (E.E.R., D.T.,
C.Y.), Clinical Research (J.K.L.), Pathology (L.H.), and Abdominal Imaging
(G.M.R.), The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd,
Houston, TX 77030; and Division of Surgical Oncology, Baylor College of
Medicine, Houston, Tex (A.M.T.)
| | - Elizabeth E. Ravenberg
- From the Departments of Imaging Physics (K.P.H., A.K., J.B.S., B.P.,
B.C.M., J.M.), Breast Imaging (N.A.E., M.B., R.M.M., A.H.A., B.E.A., R.P.C.,
W.T.Y., G.M.R.), Biostatistics (H.C., J.S., P.W.), Cancer Systems Imaging (S.Z.,
M.D.P.), Moon Shots Operations (J.B.W.), Breast Medical Oncology (E.E.R., D.T.,
C.Y.), Clinical Research (J.K.L.), Pathology (L.H.), and Abdominal Imaging
(G.M.R.), The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd,
Houston, TX 77030; and Division of Surgical Oncology, Baylor College of
Medicine, Houston, Tex (A.M.T.)
| | - Debu Tripathy
- From the Departments of Imaging Physics (K.P.H., A.K., J.B.S., B.P.,
B.C.M., J.M.), Breast Imaging (N.A.E., M.B., R.M.M., A.H.A., B.E.A., R.P.C.,
W.T.Y., G.M.R.), Biostatistics (H.C., J.S., P.W.), Cancer Systems Imaging (S.Z.,
M.D.P.), Moon Shots Operations (J.B.W.), Breast Medical Oncology (E.E.R., D.T.,
C.Y.), Clinical Research (J.K.L.), Pathology (L.H.), and Abdominal Imaging
(G.M.R.), The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd,
Houston, TX 77030; and Division of Surgical Oncology, Baylor College of
Medicine, Houston, Tex (A.M.T.)
| | - Clinton Yam
- From the Departments of Imaging Physics (K.P.H., A.K., J.B.S., B.P.,
B.C.M., J.M.), Breast Imaging (N.A.E., M.B., R.M.M., A.H.A., B.E.A., R.P.C.,
W.T.Y., G.M.R.), Biostatistics (H.C., J.S., P.W.), Cancer Systems Imaging (S.Z.,
M.D.P.), Moon Shots Operations (J.B.W.), Breast Medical Oncology (E.E.R., D.T.,
C.Y.), Clinical Research (J.K.L.), Pathology (L.H.), and Abdominal Imaging
(G.M.R.), The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd,
Houston, TX 77030; and Division of Surgical Oncology, Baylor College of
Medicine, Houston, Tex (A.M.T.)
| | - Jennifer K. Litton
- From the Departments of Imaging Physics (K.P.H., A.K., J.B.S., B.P.,
B.C.M., J.M.), Breast Imaging (N.A.E., M.B., R.M.M., A.H.A., B.E.A., R.P.C.,
W.T.Y., G.M.R.), Biostatistics (H.C., J.S., P.W.), Cancer Systems Imaging (S.Z.,
M.D.P.), Moon Shots Operations (J.B.W.), Breast Medical Oncology (E.E.R., D.T.,
C.Y.), Clinical Research (J.K.L.), Pathology (L.H.), and Abdominal Imaging
(G.M.R.), The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd,
Houston, TX 77030; and Division of Surgical Oncology, Baylor College of
Medicine, Houston, Tex (A.M.T.)
| | - Lei Huo
- From the Departments of Imaging Physics (K.P.H., A.K., J.B.S., B.P.,
B.C.M., J.M.), Breast Imaging (N.A.E., M.B., R.M.M., A.H.A., B.E.A., R.P.C.,
W.T.Y., G.M.R.), Biostatistics (H.C., J.S., P.W.), Cancer Systems Imaging (S.Z.,
M.D.P.), Moon Shots Operations (J.B.W.), Breast Medical Oncology (E.E.R., D.T.,
C.Y.), Clinical Research (J.K.L.), Pathology (L.H.), and Abdominal Imaging
(G.M.R.), The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd,
Houston, TX 77030; and Division of Surgical Oncology, Baylor College of
Medicine, Houston, Tex (A.M.T.)
| | - Alastair M. Thompson
- From the Departments of Imaging Physics (K.P.H., A.K., J.B.S., B.P.,
B.C.M., J.M.), Breast Imaging (N.A.E., M.B., R.M.M., A.H.A., B.E.A., R.P.C.,
W.T.Y., G.M.R.), Biostatistics (H.C., J.S., P.W.), Cancer Systems Imaging (S.Z.,
M.D.P.), Moon Shots Operations (J.B.W.), Breast Medical Oncology (E.E.R., D.T.,
C.Y.), Clinical Research (J.K.L.), Pathology (L.H.), and Abdominal Imaging
(G.M.R.), The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd,
Houston, TX 77030; and Division of Surgical Oncology, Baylor College of
Medicine, Houston, Tex (A.M.T.)
| | - Peng Wei
- From the Departments of Imaging Physics (K.P.H., A.K., J.B.S., B.P.,
B.C.M., J.M.), Breast Imaging (N.A.E., M.B., R.M.M., A.H.A., B.E.A., R.P.C.,
W.T.Y., G.M.R.), Biostatistics (H.C., J.S., P.W.), Cancer Systems Imaging (S.Z.,
M.D.P.), Moon Shots Operations (J.B.W.), Breast Medical Oncology (E.E.R., D.T.,
C.Y.), Clinical Research (J.K.L.), Pathology (L.H.), and Abdominal Imaging
(G.M.R.), The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd,
Houston, TX 77030; and Division of Surgical Oncology, Baylor College of
Medicine, Houston, Tex (A.M.T.)
| | - Wei T. Yang
- From the Departments of Imaging Physics (K.P.H., A.K., J.B.S., B.P.,
B.C.M., J.M.), Breast Imaging (N.A.E., M.B., R.M.M., A.H.A., B.E.A., R.P.C.,
W.T.Y., G.M.R.), Biostatistics (H.C., J.S., P.W.), Cancer Systems Imaging (S.Z.,
M.D.P.), Moon Shots Operations (J.B.W.), Breast Medical Oncology (E.E.R., D.T.,
C.Y.), Clinical Research (J.K.L.), Pathology (L.H.), and Abdominal Imaging
(G.M.R.), The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd,
Houston, TX 77030; and Division of Surgical Oncology, Baylor College of
Medicine, Houston, Tex (A.M.T.)
| | - Mark D. Pagel
- From the Departments of Imaging Physics (K.P.H., A.K., J.B.S., B.P.,
B.C.M., J.M.), Breast Imaging (N.A.E., M.B., R.M.M., A.H.A., B.E.A., R.P.C.,
W.T.Y., G.M.R.), Biostatistics (H.C., J.S., P.W.), Cancer Systems Imaging (S.Z.,
M.D.P.), Moon Shots Operations (J.B.W.), Breast Medical Oncology (E.E.R., D.T.,
C.Y.), Clinical Research (J.K.L.), Pathology (L.H.), and Abdominal Imaging
(G.M.R.), The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd,
Houston, TX 77030; and Division of Surgical Oncology, Baylor College of
Medicine, Houston, Tex (A.M.T.)
| | - Jingfei Ma
- From the Departments of Imaging Physics (K.P.H., A.K., J.B.S., B.P.,
B.C.M., J.M.), Breast Imaging (N.A.E., M.B., R.M.M., A.H.A., B.E.A., R.P.C.,
W.T.Y., G.M.R.), Biostatistics (H.C., J.S., P.W.), Cancer Systems Imaging (S.Z.,
M.D.P.), Moon Shots Operations (J.B.W.), Breast Medical Oncology (E.E.R., D.T.,
C.Y.), Clinical Research (J.K.L.), Pathology (L.H.), and Abdominal Imaging
(G.M.R.), The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd,
Houston, TX 77030; and Division of Surgical Oncology, Baylor College of
Medicine, Houston, Tex (A.M.T.)
| | - Gaiane M. Rauch
- From the Departments of Imaging Physics (K.P.H., A.K., J.B.S., B.P.,
B.C.M., J.M.), Breast Imaging (N.A.E., M.B., R.M.M., A.H.A., B.E.A., R.P.C.,
W.T.Y., G.M.R.), Biostatistics (H.C., J.S., P.W.), Cancer Systems Imaging (S.Z.,
M.D.P.), Moon Shots Operations (J.B.W.), Breast Medical Oncology (E.E.R., D.T.,
C.Y.), Clinical Research (J.K.L.), Pathology (L.H.), and Abdominal Imaging
(G.M.R.), The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd,
Houston, TX 77030; and Division of Surgical Oncology, Baylor College of
Medicine, Houston, Tex (A.M.T.)
| |
Collapse
|
16
|
Zhuang B, Cui C, He J, Xu J, Yin G, Duan X, Yue G, Wang H, Wang X, Sirajuddin A, Zhao S, Lu M. Detection of Myocardial Ischemia Using Cardiovascular MRI Stress T1 Mapping: A Miniature-Swine Validation Study. Radiol Cardiothorac Imaging 2023; 5:e220092. [PMID: 37404782 PMCID: PMC10316297 DOI: 10.1148/ryct.220092] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2022] [Revised: 03/30/2023] [Accepted: 04/18/2023] [Indexed: 07/06/2023]
Abstract
Purpose To assess the efficacy of cardiac MRI stress T1 mapping in detecting ischemic and infarcted myocardium in a miniature-swine model, using pathologic findings as the reference standard. Materials and Methods Ten adult male Chinese miniature swine, with coronary artery stenosis induced by an ameroid constrictor, and two healthy control swine were studied. Cardiac 3-T MRI rest and adenosine triphosphate stress T1 mapping and perfusion images, along with resting and late gadolinium enhancement images, were acquired at baseline and weekly up to 4 weeks after surgery or until humanely killed. A receiver operating characteristic analysis was used to analyze the performance of T1 mapping in the detection of myocardial ischemia. Results In the experimental group, both the infarcted myocardium (ΔT1 = 10 msec ± 2 [SD]; ΔT1 percentage = 0.7% ± 0.1) and ischemic myocardium (ΔT1 = 10 msec ± 2; ΔT1 percentage = 0.9% ± 0.2) exhibited reduced T1 reactivity compared with the remote myocardium (ΔT1 = 53 msec ± 7; ΔT1 percentage = 4.7% ± 0.6) and normal myocardium (ΔT1 = 56 msec ± 11; ΔT1 percentage = 4.9% ± 1.1). Receiver operating characteristic analysis demonstrated high diagnostic performance of ΔT1 in detecting ischemic myocardium, with an area under the curve (AUC) of 0.84 (P < .001). Rest T1 displayed high diagnostic performance in detecting infarcted myocardium (AUC = 0.95; P < .001). When rest T1 and ΔT1 were combined, the diagnostic performance for both ischemic and infarcted myocardium were improved (AUCs, 0.89 and 0.97, respectively; all P < .001). The collagen volume fraction correlated with ΔT1, ΔT1 percentage, and Δ extracellular volume percentage (r = -0.70, -0.70, and -0.50, respectively; P = .001, .001, and .03, respectively). Conclusion Using histopathologic validation in a swine model, noninvasive cardiac MRI stress T1 mapping demonstrated high performance in detecting ischemic and infarcted myocardium without the need for contrast agents.Keywords: Coronary Artery Disease, MRI, Myocardial Ischemia, Rest T1 Mapping, Stress T1 Mapping, Swine Model Supplemental material is available for this article. © RSNA, 2023See also commentary by Burrage and Ferreira in this issue.
Collapse
|
17
|
Wiesmueller M, Meixner CR, Weber M, Kesting M, Nagel AM, Wuest W, May MS, Roemer FW, Uder M, Heiss R. Time-of-Flight Angiography in Ultra-High-Field 7 T MRI for the Evaluation of Peroneal Perforator Arteries Before Osseomyocutaneous Flap Surgery. Invest Radiol 2023; 58:216-222. [PMID: 36165876 PMCID: PMC9914154 DOI: 10.1097/rli.0000000000000926] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2022] [Accepted: 08/11/2022] [Indexed: 10/14/2022]
Abstract
OBJECTIVES Presurgical identification and morphologic characterization of the peroneal perforator arteries (PPAs) are essential for osseomyocutaneous flap surgery. The aim of this study was to evaluate PPAs using time-of-flight (TOF) angiography in 7 T magnetic resonance imaging in comparison with dual-energy computed tomographic angiography (CTA). MATERIALS AND METHODS In this prospective study, TOF angiography and CTA of both lower legs were acquired before flap surgery from 07/2019 to 02/2020. Magnetic resonance imaging was performed using a dedicated 28-channel knee coil with an acquisition time of 9:55 minutes (voxel size: 0.4 × 0.4 × 0.8 mm). Computed tomographic angiography was acquired with a third-generation dual-source computed tomography on the same day. Virtual monoenergetic reconstructions at 40 keV photon energy served as the standard of reference for PPA identification and subtyping. Two independent readers assessed the image quality, quantity, length assessment, and classification according to surgical considerations of PPAs for TOF angiography and CTA. Both TOF angiography and CTA were used for presurgical flap design and were evaluated by an orofacial surgeon. RESULTS Ten patients (mean age, 59.9 ± 14.9 years; 7 men) were included. Time-of-flight angiography and CTA identified 53 and 51 PPAs in total, respectively. Time-of-flight angiography showed superior image quality (both readers, P < 0.05). Time-of-flight angiography enabled specific classification of PPA subtypes more often (53 vs 39; P < 0.05), and both readers reported higher diagnostic confidence for TOF angiography than CTA in all patients (interrater agreement κ = 0.8; P < 0.05). Regarding length assessment, PPAs were significantly more conspicuous with TOF angiography (TOF mean , 50 ± 11 mm; CTA mean , 40 ± 9 mm; P = 0.001). In comparison with CTA, TOF angiography prospectively changed the orofacial surgeon's final decision on the presurgical selected PPAs in 60% of cases. CONCLUSIONS Presurgical assessment of PPAs is feasible using TOF in 7 T magnetic resonance imaging. Moreover, TOF angiography was superior to CTA for classifying and identifying PPAs, which may facilitate the planning of reconstructive surgery.
Collapse
Affiliation(s)
| | | | - Manuel Weber
- Department of Oral and Maxillofacial Surgery, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany
| | - Marco Kesting
- Department of Oral and Maxillofacial Surgery, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany
| | - Armin M. Nagel
- From the Institute of Radiology, University Hospital Erlangen
- Division of Medical Physics in Radiology, German Cancer Research Centre (DKFZ), Heidelberg, Germany
| | - Wolfgang Wuest
- From the Institute of Radiology, University Hospital Erlangen
| | - Matthias S. May
- From the Institute of Radiology, University Hospital Erlangen
| | - Frank W. Roemer
- From the Institute of Radiology, University Hospital Erlangen
- Quantitative Imaging Center (QIC), Department of Radiology, Boston University School of Medicine, Massachusetts
| | - Michael Uder
- From the Institute of Radiology, University Hospital Erlangen
| | - Rafael Heiss
- From the Institute of Radiology, University Hospital Erlangen
| |
Collapse
|
18
|
Shang Y, Xie X, Luo Y, Nie F, Luo Y, Jing X, Liao J, Zheng R, Wu R, Luo X, Chen Z, Xu Y, Zhang R, Wang H, Yuan J, Zhang H, Zhu J, Zhang W, Ruan L, Yang M, Li Z, Luo H, Chen Q, Yan J, Tang C, Liu D, Fang K, Guo Y, He W. Safety findings after intravenous administration of sulfur hexafluoride microbubbles to 463,434 examinations at 24 centers. Eur Radiol 2023; 33:988-995. [PMID: 36205769 DOI: 10.1007/s00330-022-09108-4] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2022] [Revised: 07/03/2022] [Accepted: 08/04/2022] [Indexed: 02/03/2023]
Abstract
OBJECTIVES We aimed to evaluate the safety of the ultrasound contrast agent sulfur hexafluoride microbubbles in a large group of patients referred for routine contrast-enhanced ultrasound (CEUS). METHODS A retrospective assessment was made of all patients that received sulfur hexafluoride microbubbles intravenously for CEUS at 24 centers between January 2006 and April 2019. Patient demographic details, examination type, and the dose of sulfur hexafluoride microbubbles administered were recorded with specific adverse events (AEs) documentation tools at each center. All AEs were recorded as serious or non-serious. Non-serious AEs were classified by intensity as mild, moderate, or severe according to ACR criteria. The frequencies of AEs across patient subgroups were compared using the chi-square test. RESULTS A total of 463,434 examinations were evaluated. Overall, 157 AEs (153 [0.033%] non-serious; 4 [0.001%] serious) were reported after sulfur hexafluoride microbubbles administration, giving an AE frequency of 0.034% (157/463,434). Among the non-serious AEs, 66 (0.014%) were mild, 70 (0.015%) moderate, and 17 (0.004%) severe in intensity. The liver was the most common examination site, presenting an AE frequency of 0.026%. The highest AE frequency (0.092%) was for patients undergoing CEUS for vascular disease. There were no significant gender differences in either the total number or the severity of non-serious AEs (chi-square = 2.497, p = 0.287). The onset of AEs occurred within 30 min of sulfur hexafluoride microbubbles administration in 91% of cases. CONCLUSION The frequency of AEs to sulfur hexafluoride microbubbles is very low and severe reactions are rare, confirming that sulfur hexafluoride microbubbles are appropriate for routine CEUS applications. KEY POINT • The frequency of AEs to sulfur hexafluoride microbubbles is very low and severe reactions are rare.
Collapse
Affiliation(s)
- Yongning Shang
- Department of Ultrasound, Southwest Hospital, Army Medical University (Third Military Medical University), Chongqing, 400038, China
| | - Xiaoyan Xie
- Department of Medical Ultrasonics, Division of Interventional Ultrasound, Institute for the Study of Diagnostic and Interventional Ultrasound, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
| | - Yan Luo
- Department of Medical Ultrasound, West China Hospital of Sichuan University, Chengdu, China
| | - Fang Nie
- Department of Medical Ultrasonics, Lanzhou University Second Hospital, Lanzhou, China
| | - Yukun Luo
- Department of Ultrasound, Chinese PLA General Hospital, Beijing, China
| | - Xiang Jing
- Department of Ultrasound, Tianjin Third Central Hospital, Tianjin, China
| | - Jintang Liao
- Department of Medical Ultrasonics, Xiang Ya Hospital, Central South University, Changsha, China
| | - Rongqin Zheng
- Department of Ultrasound, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China
| | - Rong Wu
- Department of Ultrasound in Medical, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
| | - Xiaomao Luo
- Department of Medical Ultrasound, Yunnan Cancer Hospital, Kunming, China
| | - Zhiyi Chen
- Department of Ultrasound Medicine, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
| | - Youfeng Xu
- Department of Ultrasound, Ningbo First Hospital, Ningbo, China
| | - Ruifang Zhang
- Department of Medical Ultrasonics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
| | - Hui Wang
- Department of Ultrasound, China-Japan Union Hospital, Jilin University, Changchun, China
| | - Jianjun Yuan
- Department of Ultrasonography, The People's Hospital of Zhengzhou University, Zhengzhou, China
| | - Hongxia Zhang
- Department of Ultrasound, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
| | - Jiaan Zhu
- Department of Ultrasound, Peking University People's Hospital, Beijing, China
| | - Wei Zhang
- Department of Ultrasound, The Third Affiliated Hospital of Guangxi Medical University, Nanjing, China
| | - Litao Ruan
- Department of Ultrasound Medicine, The First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, China
| | - Min Yang
- Department of Ultrasound, Beijing Shijitan Hospital, Capital Medical University, Beijing, China
| | - Zhiyan Li
- Department of Ultrasound, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China
| | - Hong Luo
- Department of Ultrasound, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
| | - Qin Chen
- Department of Ultrasonic Medicine, West China Second University Hospital, Sichuan University, Chengdu, China
| | - Jiping Yan
- Department of Ultrasound, People's Hospital of Shanxi Province, Taiyuan, China
| | - Chunlin Tang
- Department of Ultrasound, Southwest Hospital, Army Medical University (Third Military Medical University), Chongqing, 400038, China
| | - Deng Liu
- Department of Ultrasound, Southwest Hospital, Army Medical University (Third Military Medical University), Chongqing, 400038, China
| | - Kejing Fang
- Department of Ultrasound, Southwest Hospital, Army Medical University (Third Military Medical University), Chongqing, 400038, China
| | - Yanli Guo
- Department of Ultrasound, Southwest Hospital, Army Medical University (Third Military Medical University), Chongqing, 400038, China.
- Department of Ultrasound, Southwest Hospital, Army Medical University (Third Military Medical University), Gaotanyan street No.30, Shapingba Distract, Chongqing, China.
| | - Wen He
- Department of Ultrasound, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
- Department of Ultrasound, Beijing Tiantan Hospital, Capital Medical University, Tiantan Xili No.6, Dongcheng District, Beijing, China.
| |
Collapse
|
19
|
Joshi SR, Salinas W, Khan DA. Drug Hypersensitivity. Clin Immunol 2023. [DOI: 10.1016/b978-0-7020-8165-1.00050-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/09/2023]
|
20
|
Hua N, Minaeva O, Lupoli N, Franz ES, Liu X, Moncaster JA, Babcock KJ, Jara H, Tripodis Y, Guermazi A, Soto JA, Anderson SW, Goldstein LE. Gadolinium Deposition in the Rat Brain Measured with Quantitative MRI versus Elemental Mass Spectrometry. Radiology 2023; 306:244-251. [PMID: 36125373 PMCID: PMC9792715 DOI: 10.1148/radiol.212171] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2021] [Revised: 06/08/2022] [Accepted: 07/15/2022] [Indexed: 01/19/2023]
Abstract
Background T1-weighted MRI and quantitative longitudinal relaxation rate (R1) mapping have been used to evaluate gadolinium retention in the brain after gadolinium-based contrast agent (GBCA) administration. Whether MRI measures accurately reflect gadolinium regional distribution and concentration in the brain remains unclear. Purpose To compare gadolinium retention in rat forebrain measured with in vivo quantitative MRI R1 and ex vivo laser ablation inductively coupled plasma mass spectrometry (LA-ICP-MS) mapping after gadobenate, gadopentetate, gadodiamide, or gadobutrol administration. Materials and Methods Adult female Sprague-Dawley rats were randomly assigned to one of five groups (eight per group) and administered gadobenate, gadopentetate, gadodiamide, gadobutrol (2.4 mmol/kg per week for 5 weeks), or saline (4.8 mL/kg per week for 5 weeks). MRI R1 mapping was performed at baseline and 1 week after the final injection to determine R1 and ΔR1. Postmortem brains from the same rats were analyzed with LA-ICP-MS elemental mapping to determine regional gadolinium concentrations. Student t tests were performed to compare results between GBCA and saline groups. Results Rats that were administered gadobenate showed gadolinium-related MRI ΔR1 in 39.5% of brain volume (ΔR1 = 0.087 second-1 ± 0.051); gadopentetate, 20.6% (ΔR1 = 0.069 second-1 ± 0.018); gadodiamide, 5.4% (ΔR1 = 0.055 second-1 ± 0.019); and gadobutrol, 2.2% (ΔR1 = 0.052 second-1 ± 0.041). Agent-specific gadolinium-related ΔR1 was detected in multiple forebrain regions (neocortex, hippocampus, dentate gyrus, thalamus, and caudate-putamen) in rats treated with gadobenate or gadopentetate, whereas rats treated with gadodiamide showed gadolinium-related ΔR1 in caudate-putamen. By contrast, LA-ICP-MS elemental mapping showed a similar regional distribution pattern of heterogeneous retained gadolinium in the forebrain of rats treated with gadobenate, gadopentetate, or gadodiamide, with the average gadolinium concentration of 0.45 μg · g-1 ± 0.07, 0.50 μg · g-1 ± 0.10, and 0.60 μg · g-1 ± 0.11, respectively. Low levels (0.01 μg · g-1 ± 0.00) of retained gadolinium were detected in the forebrain of gadobutrol-treated rats. Conclusion Differences in in vivo MRI longitudinal relaxation rate versus ex vivo elemental mass spectrometry measures of retained gadolinium in rat forebrains suggest that some forms of retained gadolinium may escape detection with MRI. © RSNA, 2022 Online supplemental material is available for this article.
Collapse
Affiliation(s)
| | | | - Nicola Lupoli
- From the Departments of Radiology (N.H., O.M., N.L., X.L., J.A.M.,
H.J., A.G., J.A.S., S.W.A., L.E.G.), Neurology (L.E.G.), Pathology &
Laboratory Medicine (L.E.G.), Anatomy & Neurobiology (K.J.B.), and
Biostatistics (Y.T.), Boston University School of Medicine, 670 Albany St, 4th
Floor, Boston, MA 02118; Boston University Alzheimer’s Disease Research
Center (N.H., O.M., J.A.M., L.E.G.), Boston, Mass; and Center for Biometallomics
(O.M., N.L., J.A.M., L.E.G.), College of Engineering (E.S.F., S.W.A., L.E.G.),
and Photonics Center (O.M., J.A.M., S.W.A., L.E.G.), Boston University, Boston,
Mass
| | - Erich S. Franz
- From the Departments of Radiology (N.H., O.M., N.L., X.L., J.A.M.,
H.J., A.G., J.A.S., S.W.A., L.E.G.), Neurology (L.E.G.), Pathology &
Laboratory Medicine (L.E.G.), Anatomy & Neurobiology (K.J.B.), and
Biostatistics (Y.T.), Boston University School of Medicine, 670 Albany St, 4th
Floor, Boston, MA 02118; Boston University Alzheimer’s Disease Research
Center (N.H., O.M., J.A.M., L.E.G.), Boston, Mass; and Center for Biometallomics
(O.M., N.L., J.A.M., L.E.G.), College of Engineering (E.S.F., S.W.A., L.E.G.),
and Photonics Center (O.M., J.A.M., S.W.A., L.E.G.), Boston University, Boston,
Mass
| | - Xiuping Liu
- From the Departments of Radiology (N.H., O.M., N.L., X.L., J.A.M.,
H.J., A.G., J.A.S., S.W.A., L.E.G.), Neurology (L.E.G.), Pathology &
Laboratory Medicine (L.E.G.), Anatomy & Neurobiology (K.J.B.), and
Biostatistics (Y.T.), Boston University School of Medicine, 670 Albany St, 4th
Floor, Boston, MA 02118; Boston University Alzheimer’s Disease Research
Center (N.H., O.M., J.A.M., L.E.G.), Boston, Mass; and Center for Biometallomics
(O.M., N.L., J.A.M., L.E.G.), College of Engineering (E.S.F., S.W.A., L.E.G.),
and Photonics Center (O.M., J.A.M., S.W.A., L.E.G.), Boston University, Boston,
Mass
| | - Juliet A. Moncaster
- From the Departments of Radiology (N.H., O.M., N.L., X.L., J.A.M.,
H.J., A.G., J.A.S., S.W.A., L.E.G.), Neurology (L.E.G.), Pathology &
Laboratory Medicine (L.E.G.), Anatomy & Neurobiology (K.J.B.), and
Biostatistics (Y.T.), Boston University School of Medicine, 670 Albany St, 4th
Floor, Boston, MA 02118; Boston University Alzheimer’s Disease Research
Center (N.H., O.M., J.A.M., L.E.G.), Boston, Mass; and Center for Biometallomics
(O.M., N.L., J.A.M., L.E.G.), College of Engineering (E.S.F., S.W.A., L.E.G.),
and Photonics Center (O.M., J.A.M., S.W.A., L.E.G.), Boston University, Boston,
Mass
| | - Katharine J. Babcock
- From the Departments of Radiology (N.H., O.M., N.L., X.L., J.A.M.,
H.J., A.G., J.A.S., S.W.A., L.E.G.), Neurology (L.E.G.), Pathology &
Laboratory Medicine (L.E.G.), Anatomy & Neurobiology (K.J.B.), and
Biostatistics (Y.T.), Boston University School of Medicine, 670 Albany St, 4th
Floor, Boston, MA 02118; Boston University Alzheimer’s Disease Research
Center (N.H., O.M., J.A.M., L.E.G.), Boston, Mass; and Center for Biometallomics
(O.M., N.L., J.A.M., L.E.G.), College of Engineering (E.S.F., S.W.A., L.E.G.),
and Photonics Center (O.M., J.A.M., S.W.A., L.E.G.), Boston University, Boston,
Mass
| | - Hernán Jara
- From the Departments of Radiology (N.H., O.M., N.L., X.L., J.A.M.,
H.J., A.G., J.A.S., S.W.A., L.E.G.), Neurology (L.E.G.), Pathology &
Laboratory Medicine (L.E.G.), Anatomy & Neurobiology (K.J.B.), and
Biostatistics (Y.T.), Boston University School of Medicine, 670 Albany St, 4th
Floor, Boston, MA 02118; Boston University Alzheimer’s Disease Research
Center (N.H., O.M., J.A.M., L.E.G.), Boston, Mass; and Center for Biometallomics
(O.M., N.L., J.A.M., L.E.G.), College of Engineering (E.S.F., S.W.A., L.E.G.),
and Photonics Center (O.M., J.A.M., S.W.A., L.E.G.), Boston University, Boston,
Mass
| | - Yorghos Tripodis
- From the Departments of Radiology (N.H., O.M., N.L., X.L., J.A.M.,
H.J., A.G., J.A.S., S.W.A., L.E.G.), Neurology (L.E.G.), Pathology &
Laboratory Medicine (L.E.G.), Anatomy & Neurobiology (K.J.B.), and
Biostatistics (Y.T.), Boston University School of Medicine, 670 Albany St, 4th
Floor, Boston, MA 02118; Boston University Alzheimer’s Disease Research
Center (N.H., O.M., J.A.M., L.E.G.), Boston, Mass; and Center for Biometallomics
(O.M., N.L., J.A.M., L.E.G.), College of Engineering (E.S.F., S.W.A., L.E.G.),
and Photonics Center (O.M., J.A.M., S.W.A., L.E.G.), Boston University, Boston,
Mass
| | - Ali Guermazi
- From the Departments of Radiology (N.H., O.M., N.L., X.L., J.A.M.,
H.J., A.G., J.A.S., S.W.A., L.E.G.), Neurology (L.E.G.), Pathology &
Laboratory Medicine (L.E.G.), Anatomy & Neurobiology (K.J.B.), and
Biostatistics (Y.T.), Boston University School of Medicine, 670 Albany St, 4th
Floor, Boston, MA 02118; Boston University Alzheimer’s Disease Research
Center (N.H., O.M., J.A.M., L.E.G.), Boston, Mass; and Center for Biometallomics
(O.M., N.L., J.A.M., L.E.G.), College of Engineering (E.S.F., S.W.A., L.E.G.),
and Photonics Center (O.M., J.A.M., S.W.A., L.E.G.), Boston University, Boston,
Mass
| | - Jorge A. Soto
- From the Departments of Radiology (N.H., O.M., N.L., X.L., J.A.M.,
H.J., A.G., J.A.S., S.W.A., L.E.G.), Neurology (L.E.G.), Pathology &
Laboratory Medicine (L.E.G.), Anatomy & Neurobiology (K.J.B.), and
Biostatistics (Y.T.), Boston University School of Medicine, 670 Albany St, 4th
Floor, Boston, MA 02118; Boston University Alzheimer’s Disease Research
Center (N.H., O.M., J.A.M., L.E.G.), Boston, Mass; and Center for Biometallomics
(O.M., N.L., J.A.M., L.E.G.), College of Engineering (E.S.F., S.W.A., L.E.G.),
and Photonics Center (O.M., J.A.M., S.W.A., L.E.G.), Boston University, Boston,
Mass
| | - Stephan W. Anderson
- From the Departments of Radiology (N.H., O.M., N.L., X.L., J.A.M.,
H.J., A.G., J.A.S., S.W.A., L.E.G.), Neurology (L.E.G.), Pathology &
Laboratory Medicine (L.E.G.), Anatomy & Neurobiology (K.J.B.), and
Biostatistics (Y.T.), Boston University School of Medicine, 670 Albany St, 4th
Floor, Boston, MA 02118; Boston University Alzheimer’s Disease Research
Center (N.H., O.M., J.A.M., L.E.G.), Boston, Mass; and Center for Biometallomics
(O.M., N.L., J.A.M., L.E.G.), College of Engineering (E.S.F., S.W.A., L.E.G.),
and Photonics Center (O.M., J.A.M., S.W.A., L.E.G.), Boston University, Boston,
Mass
| | - Lee E. Goldstein
- From the Departments of Radiology (N.H., O.M., N.L., X.L., J.A.M.,
H.J., A.G., J.A.S., S.W.A., L.E.G.), Neurology (L.E.G.), Pathology &
Laboratory Medicine (L.E.G.), Anatomy & Neurobiology (K.J.B.), and
Biostatistics (Y.T.), Boston University School of Medicine, 670 Albany St, 4th
Floor, Boston, MA 02118; Boston University Alzheimer’s Disease Research
Center (N.H., O.M., J.A.M., L.E.G.), Boston, Mass; and Center for Biometallomics
(O.M., N.L., J.A.M., L.E.G.), College of Engineering (E.S.F., S.W.A., L.E.G.),
and Photonics Center (O.M., J.A.M., S.W.A., L.E.G.), Boston University, Boston,
Mass
| |
Collapse
|
21
|
MacLeod CA, Gauthier I, Davenport MS, McGrath TA, Khan F, Dos Santos MP, McInnes MDF, Schieda N. Adverse Events Associated with Intra-Arterial Administration of Gadolinium-Based Contrast Agents: A Systematic Review and Meta-Analysis. J Vasc Interv Radiol 2022; 34:568-577.e10. [PMID: 36464013 DOI: 10.1016/j.jvir.2022.11.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2022] [Revised: 11/08/2022] [Accepted: 11/19/2022] [Indexed: 12/03/2022] Open
Abstract
PURPOSE To determine the risk of immediate hypersensitivity reactions (HRs), contrast-associated acute kidney injury (CA-AKI), nephrogenic systemic fibrosis (NSF), and gadolinium retention associated with use of intra-arterial gadolinium-based contrast agents (GBCAs). MATERIALS AND METHODS MEDLINE, Embase, and Cochrane Central Register of Controlled Trials were searched from 1988 (GBCAs approved for clinical use) to March 2021 for studies reporting adverse events associated with intra-arterial administration of GBCAs. The number of adverse events and GBCA administrations were used to calculate incidence in individual studies, and results across studies were pooled using random-effects meta-analysis. RESULTS There were 72 studies (patients = 1,221) that reported on HR, 59 studies (patients = 1,142) that reported on CA-AKI, and 6 studies (patients = 291) that reported on NSF. No studies reported gadolinium retention as an outcome. Based on 5 events and 1,451 GBCA administrations, the incidence of HR per 100 administrations was 0.95 (95% CI, 0.52-1.51). Based on 90 events and 1,318 GBCA administrations, the incidence of CA-AKI per 100 administrations was 5.94 (95% CI, 3.92-8.34). Based on 7 events and 361 GBCA administrations, the incidence of NSF per 100 Group I GBCA administrations was 4.72 (95% CI, 0.35-13.70). There were no unconfounded NSF events after Group II GBCA administration. CONCLUSIONS HRs to intra-arterial administration of GBCAs are rare, with no serious reactions. Limited data demonstrate a higher-than-expected rate of CA-AKI; however, multiple confounding factors were noted. Thus, any causative link of CA-AKI to GBCA remains controversial. Also, severe physiologic reactions (including life-threatening arrhythmias) during coronary angiography have been reported.
Collapse
Affiliation(s)
- Chad A MacLeod
- Department of Radiology, University of Ottawa, Ottawa, Ontario, Canada
| | - Isabelle Gauthier
- Department of Radiology, University of Ottawa, Ottawa, Ontario, Canada
| | - Matthew S Davenport
- Department of Radiology, Michigan Medicine, University of Michigan, Ann Arbor, Michigan
| | - Trevor A McGrath
- Department of Radiology, University of Ottawa, Ottawa, Ontario, Canada
| | - Faizan Khan
- School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
| | | | - Mathew D F McInnes
- Department of Radiology, University of Ottawa, Ottawa, Ontario, Canada; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; Department of Epidemiology, University of Ottawa, Ottawa, Ontario, Canada
| | - Nicola Schieda
- Department of Radiology, University of Ottawa, Ottawa, Ontario, Canada; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
| |
Collapse
|
22
|
Safety considerations related to intravenous contrast agents in pediatric imaging. Pediatr Radiol 2022:10.1007/s00247-022-05470-z. [PMID: 35941280 DOI: 10.1007/s00247-022-05470-z] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/29/2022] [Revised: 05/25/2022] [Accepted: 07/22/2022] [Indexed: 10/15/2022]
Abstract
Intravenous contrast media are used in MRI, CT and US studies for anatomical evaluation and lesion characterization. Safety is always of paramount importance when administering any contrast media to children, and it is important for radiologists and ordering providers to be knowledgeable of the safety profiles and potential adverse events that can occur. This manuscript reviews the frequency and types of adverse events associated with intravenous contrast agents reported in the pediatric literature. Overall, intravenous contrast agents are very safe to use in children. However, familiarity with how to treat and prevent these uncommon events is crucial in preventing poor outcomes. In addition, an understanding of gadolinium deposition in tissues can help facilitate conversations with concerned physicians and parents. This review provides a concise yet comprehensive reference for radiologists and ordering providers on intravenous contrast safety considerations in the pediatric patient.
Collapse
|
23
|
Contrast Media Adverse Drug Reactions in Highly Polluted Environment. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH 2022; 19:ijerph19127077. [PMID: 35742323 PMCID: PMC9223239 DOI: 10.3390/ijerph19127077] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/18/2022] [Revised: 06/06/2022] [Accepted: 06/08/2022] [Indexed: 01/27/2023]
Abstract
Iodinated- (ICM) and gadolinium-based (GCM) contrast media are used in radiology imaging techniques, such as computer tomography (CT) and magnetic resonance (MR), respectively. The paper aims to analyze the adverse drug reactions of ICM and GCM on different sites of the body in a highly polluted environment. We analyzed the pharmacovigilance in contrast media on the basis of reports submitted to the Regional Center for Monitoring of Adverse Drug Reactions (ADR) at the Department of Clinical Pharmacology in Wrocław. Safety profiles were compared between different ICM and GCM and at the system organ level using the proportional reporting ratio (PRR). We analyzed 124 reports of adverse reactions related to contrast agents between 2006 and 2021. Our findings revealed that ADR combinations occurred more frequently after the use of iodinated contrast agents (72.08%) than gadolinium contrast agents (27.92%). Iomeprol and Iopromide were identified as the most frequently reported media. Each medium presented a different safety profile. Skin disorders are the most common adverse drug reactions among patients using both iodine- and gadolinium-based contrast media. Gadolinium-based contrast agents are characterized by similar organ toxicity. Conversely, iodine-based contrast agents are more diverse—some of which show tissue specificity, such as Iodixanol for the gastrointestinal system or Iohexol for the respiratory tract. This study shows relatively high occurrence of respiratory tract related ADRs in Wrocław. We also prove that it is possible to choose the most optimal contrast agent for patients with specific organ site problems to omit the possible complications.
Collapse
|
24
|
Mann RM, Athanasiou A, Baltzer PAT, Camps-Herrero J, Clauser P, Fallenberg EM, Forrai G, Fuchsjäger MH, Helbich TH, Killburn-Toppin F, Lesaru M, Panizza P, Pediconi F, Pijnappel RM, Pinker K, Sardanelli F, Sella T, Thomassin-Naggara I, Zackrisson S, Gilbert FJ, Kuhl CK. Breast cancer screening in women with extremely dense breasts recommendations of the European Society of Breast Imaging (EUSOBI). Eur Radiol 2022; 32:4036-4045. [PMID: 35258677 PMCID: PMC9122856 DOI: 10.1007/s00330-022-08617-6] [Citation(s) in RCA: 149] [Impact Index Per Article: 74.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2021] [Revised: 01/21/2022] [Accepted: 01/27/2022] [Indexed: 02/07/2023]
Abstract
Breast density is an independent risk factor for the development of breast cancer and also decreases the sensitivity of mammography for screening. Consequently, women with extremely dense breasts face an increased risk of late diagnosis of breast cancer. These women are, therefore, underserved with current mammographic screening programs. The results of recent studies reporting on contrast-enhanced breast MRI as a screening method in women with extremely dense breasts provide compelling evidence that this approach can enable an important reduction in breast cancer mortality for these women and is cost-effective. Because there is now a valid option to improve breast cancer screening, the European Society of Breast Imaging (EUSOBI) recommends that women should be informed about their breast density. EUSOBI thus calls on all providers of mammography screening to share density information with the women being screened. In light of the available evidence, in women aged 50 to 70 years with extremely dense breasts, the EUSOBI now recommends offering screening breast MRI every 2 to 4 years. The EUSOBI acknowledges that it may currently not be possible to offer breast MRI immediately and everywhere and underscores that quality assurance procedures need to be established, but urges radiological societies and policymakers to act on this now. Since the wishes and values of individual women differ, in screening the principles of shared decision-making should be embraced. In particular, women should be counselled on the benefits and risks of mammography and MRI-based screening, so that they are capable of making an informed choice about their preferred screening method. KEY POINTS: • The recommendations in Figure 1 summarize the key points of the manuscript.
Collapse
Affiliation(s)
- Ritse M Mann
- Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525 GA, Nijmegen, Netherlands.
- The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, Netherlands.
| | - Alexandra Athanasiou
- Breast Imaging Department, MITERA Hospital, 6, Erithrou Stavrou Str. 151 23 Marousi, Athens, Greece
| | - Pascal A T Baltzer
- Department of Biomedical Imaging and Image-guided Therapy, Division of General and Pediatric Radiology, Research Group: Molecular and Gender Imaging, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Wien, Austria
| | - Julia Camps-Herrero
- Hospitales Ribera Salud, Avda.Cortes Valencianas, 58, 46015, Valencia, Spain
| | - Paola Clauser
- Department of Biomedical Imaging and Image-guided Therapy, Division of General and Pediatric Radiology, Research Group: Molecular and Gender Imaging, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Wien, Austria
| | - Eva M Fallenberg
- Department of Diagnostic and Interventional Radiology, School of Medicine &; Klinikum Rechts der Isar, Technical University of Munich, Munich (TUM), Ismaninger Str. 22, 81675, München, Germany
| | - Gabor Forrai
- Department of Radiology, Duna Medical Center, Budapest, Hungary
| | - Michael H Fuchsjäger
- Division of General Radiology, Department of Radiology, Medical University Graz, Auenbruggerplatz 9, 8036, Graz, Austria
| | - Thomas H Helbich
- Department of Biomedical Imaging and Image-guided Therapy, Division of General and Pediatric Radiology, Research Group: Molecular and Gender Imaging, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Wien, Austria
| | - Fleur Killburn-Toppin
- Department of Radiology, University of Cambridge, Cambridge Biomedical Campus, Hills road, Cambridge, CB20QQ, UK
| | - Mihai Lesaru
- Radiology and Imaging Laboratory, Carol Davila University, Bucharest, Romania
| | - Pietro Panizza
- Breast Imaging Unit, IRCCS Ospedale San Raffaele,, Via Olgettina 60, 20132, Milan, Italy
| | - Federica Pediconi
- Department of Radiological, Oncological and Pathological Sciences, Sapienza University of Rome, Viale Regina Elena, 324, 00161, Rome, Italy
| | - Ruud M Pijnappel
- Department of Imaging, University Medical Centre Utrecht, Utrecht University, Heidelberglaan 100, 3584 CX, Utrecht, Netherlands
- Dutch Expert Centre for Screening (LRCB), Wijchenseweg 101, 6538 SW, Nijmegen, Netherlands
| | - Katja Pinker
- Department of Biomedical Imaging and Image-guided Therapy, Division of General and Pediatric Radiology, Research Group: Molecular and Gender Imaging, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Wien, Austria
- Department of Radiology, Breast Imaging Service, Memorial Sloan Kettering Cancer Center, 300 E 66th Street, New York, NY, 10065, USA
| | - Francesco Sardanelli
- Unit of Radiology, IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy
- Department of Biomedical Sciences for Health, Università degli Studi di Milano, Via Morandi 30, 20097 San Donato Milanese, Milan, Italy
| | - Tamar Sella
- Department of Diagnostic Imaging, Hadassah Hebrew University Medical Center, Jerusalem, Israel
| | - Isabelle Thomassin-Naggara
- Department of Radiology, Sorbonne Université, APHP, Hôpital Tenon, 4, rue de la Chine, 75020, Paris, France
| | - Sophia Zackrisson
- Diagnostic Radiology, Department of Translational Medicine, Faculty of Medicine, Lund University, Skåne University Hospital Malmö, SE-205 02, Malmö, Sweden
| | - Fiona J Gilbert
- Department of Radiology, University of Cambridge, Cambridge Biomedical Campus, Hills road, Cambridge, CB20QQ, UK
| | - Christiane K Kuhl
- University Hospital of Aachen, Rheinisch-Westfälische Technische Hochschule, Pauwelsstraße30, 52074, Aachen, Germany
| |
Collapse
|
25
|
Tan CH, Chou SC, Inmutto N, Ma K, Sheng R, Shi Y, Zhou Z, Yamada A, Tateishi R. Gadoxetate-Enhanced MRI as a Diagnostic Tool in the Management of Hepatocellular Carcinoma: Report from a 2020 Asia-Pacific Multidisciplinary Expert Meeting. Korean J Radiol 2022; 23:697-719. [PMID: 35555884 PMCID: PMC9240294 DOI: 10.3348/kjr.2021.0593] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2021] [Revised: 02/21/2022] [Accepted: 03/17/2022] [Indexed: 12/04/2022] Open
Abstract
Gadoxetate magnetic resonance imaging (MRI) is widely used in clinical practice for liver imaging. For optimal use, we must understand both its advantages and limitations. This article is the outcome of an online advisory board meeting and subsequent discussions by a multidisciplinary group of experts on liver diseases across the Asia-Pacific region, first held on September 28, 2020. Here, we review the technical considerations for the use of gadoxetate, its current role in the management of patients with hepatocellular carcinoma (HCC), and its relevance in consensus guidelines for HCC imaging diagnosis. In the latter part of this review, we examine recent evidence evaluating the impact of gadoxetate on clinical outcomes on a continuum from diagnosis to treatment decision-making and follow-up. In conclusion, we outline the potential future roles of gadoxetate MRI based on an evolving understanding of the clinical utility of this contrast agent in the management of patients at risk of, or with, HCC.
Collapse
Affiliation(s)
- Cher Heng Tan
- Department of Diagnostic Radiology, Tan Tock Seng Hospital, Singapore.,Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore.
| | - Shu-Cheng Chou
- Division of General Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei City & Institute of Clinical Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan
| | - Nakarin Inmutto
- Department of Radiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
| | - Ke Ma
- Department of Infectious Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - RuoFan Sheng
- Department of Radiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Medical Imaging, Shanghai, China
| | - YingHong Shi
- Department of Liver Surgery, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China
| | - Zhongguo Zhou
- Department of Hepatobiliary Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China
| | - Akira Yamada
- Department of Radiology, Shinshu University School of Medicine, Matsumoto, Japan
| | - Ryosuke Tateishi
- Department of Gastroenterology, The University of Tokyo Hospital, Tokyo, Japan
| |
Collapse
|
26
|
Cheong BYC, Wilson JM, Preventza OA, Muthupillai R. Gadolinium-Based Contrast Agents: Updates and Answers to Typical Questions Regarding Gadolinium Use. Tex Heart Inst J 2022; 49:482255. [PMID: 35612906 DOI: 10.14503/thij-21-7680] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
Gadolinium-based contrast agents have expanded the diagnostic usefulness and capability of magnetic resonance imaging. Despite their highly favorable safety profile, these agents have been associated with nephrogenic systemic fibrosis in a small number of patients who have advanced kidney disease. Recently, trace amounts of gadolinium deposition in the brain and other organs have been reported after contrast exposure, even in patients with normal renal function. In this review, we provide a brief overview of recent updates and discuss typical clinical situations related to the use of gadolinium-based contrast agents.
Collapse
Affiliation(s)
- Benjamin Y C Cheong
- Department of Cardiology, Texas Heart Institute, Houston, Texas.,Department of Cardiovascular Radiology, Texas Heart Institute, Houston, Texas
| | - James M Wilson
- Houston Methodist DeBakey Heart & Vascular Center, Houston, Texas
| | - Ourania A Preventza
- Division of Cardiothoracic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas.,Department of Cardiovascular Surgery, Texas Heart Institute, Houston, Texas
| | - Raja Muthupillai
- Department of Cardiovascular Radiology, Texas Heart Institute, Houston, Texas.,University of Houston College of Medicine, Houston, Texas
| |
Collapse
|
27
|
Hötker AM, Vargas HA, Donati OF. Abbreviated MR Protocols in Prostate MRI. Life (Basel) 2022; 12:life12040552. [PMID: 35455043 PMCID: PMC9029675 DOI: 10.3390/life12040552] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2022] [Revised: 03/15/2022] [Accepted: 03/17/2022] [Indexed: 11/16/2022] Open
Abstract
Prostate MRI is an integral part of the clinical work-up in biopsy-naïve patients with suspected prostate cancer, and its use has been increasing steadily over the last years. To further its general availability and the number of men benefitting from it and to reduce the costs associated with MR, several approaches have been developed to shorten examination times, e.g., by focusing on sequences that provide the most useful information, employing new technological achievements, or improving the workflow in the MR suite. This review highlights these approaches; discusses their implications, advantages, and disadvantages; and serves as a starting point whenever an abbreviated prostate MRI protocol is being considered for implementation in clinical routine.
Collapse
Affiliation(s)
- Andreas M. Hötker
- Institute of Diagnostic and Interventional Radiology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland;
- Correspondence:
| | - Hebert Alberto Vargas
- Memorial Sloan Kettering Cancer Center, Department of Radiology, New York, NY 10065, USA;
| | - Olivio F. Donati
- Institute of Diagnostic and Interventional Radiology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland;
| |
Collapse
|
28
|
Jiang Z, Xia B, Ren F, Bao B, Xing W, He T, Li Z. Boosting Vascular Imaging-Performance and Systemic Biosafety of Ultra-Small NaGdF 4 Nanoparticles via Surface Engineering with Rationally Designed Novel Hydrophilic Block Co-Polymer. SMALL METHODS 2022; 6:e2101145. [PMID: 35107219 DOI: 10.1002/smtd.202101145] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/15/2021] [Revised: 12/03/2021] [Indexed: 06/14/2023]
Abstract
Revealing the anatomical structures, functions, and distribution of vasculature via contrast agent (CA) enhanced magnetic resonance imaging (MRI) is crucial for precise medical diagnosis and therapy. The clinically used MRI CAs strongly rely on Gd-chelates, which exhibit low T1 relaxivities and high risks of nephrogenic systemic fibrosis (NSF) for patients with renal dysfunction. It is extremely important to develop high-performance and safe CAs for MRI. Herein, it is reported that ultra-small NaGdF4 nanoparticles (UGNs) can serve as an excellent safe MRI CA via surface engineering with rationally designed novel hydrophilic block co-polymer (BPn ). By optimizing the polymer molecular weights, the polymer-functionalized UGNs (i.e., UGNs-BP14 ) are obtained to exhibit remarkably higher relaxivity (11.8 mm-1 s-1 at 3.0 T) than Gd-DTPA (3.6 mm-1 s-1 ) due to their ultracompact and abundant hydrophilic surface coating. The high performance of UGNs-BP14 enables us to sensitively visualize microvasculature with a small diameter of ≈0.17 mm for up to 2 h, which is the thinnest blood vessel and the longest time window for low field (1.0 T) MR angiography ever reported, and cannot be achieved by using the clinically used Gd-DTPA under the same conditions. More importantly, renal clearable UGNs-BP14 show lower risks of inducing NSF in comparison with Gd-DTPA due to their negligible release of Gd3+ ions after modification with the novel hydrophilic block copolymer. The study presents a novel avenue for boosting imaging-performance and systemic biosafety of UGNs as a robust MRI CA with great potential in precise diagnosis of vasculature-related diseases.
Collapse
Affiliation(s)
- Zhilin Jiang
- Center for Molecular Imaging and Nuclear Medicine, State Key Laboratory of Radiation Medicine and Protection, School for Radiological and Interdisciplinary Sciences (RAD-X), Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions, Soochow University, Suzhou, 215123, P. R. China
| | - Bin Xia
- School of Chemistry and Chemical Engineering, Anhui Province Key Laboratory of Advanced Catalytic Materials and Reaction Engineering, Hefei University of Technology, Hefei, Anhui, 230009, P. R. China
| | - Feng Ren
- Center for Molecular Imaging and Nuclear Medicine, State Key Laboratory of Radiation Medicine and Protection, School for Radiological and Interdisciplinary Sciences (RAD-X), Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions, Soochow University, Suzhou, 215123, P. R. China
| | - Bolin Bao
- Center for Molecular Imaging and Nuclear Medicine, State Key Laboratory of Radiation Medicine and Protection, School for Radiological and Interdisciplinary Sciences (RAD-X), Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions, Soochow University, Suzhou, 215123, P. R. China
- Department of Radiology, Affiliated Hospital 3, Soochow University, Changzhou, 213003, P. R. China
| | - Wei Xing
- Department of Radiology, Affiliated Hospital 3, Soochow University, Changzhou, 213003, P. R. China
| | - Tao He
- School of Chemistry and Chemical Engineering, Anhui Province Key Laboratory of Advanced Catalytic Materials and Reaction Engineering, Hefei University of Technology, Hefei, Anhui, 230009, P. R. China
| | - Zhen Li
- Center for Molecular Imaging and Nuclear Medicine, State Key Laboratory of Radiation Medicine and Protection, School for Radiological and Interdisciplinary Sciences (RAD-X), Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions, Soochow University, Suzhou, 215123, P. R. China
| |
Collapse
|
29
|
Huang J, Chen Z, Park SW, Lai JHC, Chan KWY. Molecular Imaging of Brain Tumors and Drug Delivery Using CEST MRI: Promises and Challenges. Pharmaceutics 2022; 14:451. [PMID: 35214183 PMCID: PMC8880023 DOI: 10.3390/pharmaceutics14020451] [Citation(s) in RCA: 12] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2022] [Revised: 02/16/2022] [Accepted: 02/17/2022] [Indexed: 12/10/2022] Open
Abstract
Chemical exchange saturation transfer (CEST) magnetic resonance imaging (MRI) detects molecules in their natural forms in a sensitive and non-invasive manner. This makes it a robust approach to assess brain tumors and related molecular alterations using endogenous molecules, such as proteins/peptides, and drugs approved for clinical use. In this review, we will discuss the promises of CEST MRI in the identification of tumors, tumor grading, detecting molecular alterations related to isocitrate dehydrogenase (IDH) and O-6-methylguanine-DNA methyltransferase (MGMT), assessment of treatment effects, and using multiple contrasts of CEST to develop theranostic approaches for cancer treatments. Promising applications include (i) using the CEST contrast of amide protons of proteins/peptides to detect brain tumors, such as glioblastoma multiforme (GBM) and low-grade gliomas; (ii) using multiple CEST contrasts for tumor stratification, and (iii) evaluation of the efficacy of drug delivery without the need of metallic or radioactive labels. These promising applications have raised enthusiasm, however, the use of CEST MRI is not trivial. CEST contrast depends on the pulse sequences, saturation parameters, methods used to analyze the CEST spectrum (i.e., Z-spectrum), and, importantly, how to interpret changes in CEST contrast and related molecular alterations in the brain. Emerging pulse sequence designs and data analysis approaches, including those assisted with deep learning, have enhanced the capability of CEST MRI in detecting molecules in brain tumors. CEST has become a specific marker for tumor grading and has the potential for prognosis and theranostics in brain tumors. With increasing understanding of the technical aspects and associated molecular alterations detected by CEST MRI, this young field is expected to have wide clinical applications in the near future.
Collapse
Affiliation(s)
- Jianpan Huang
- Department of Biomedical Engineering, City University of Hong Kong, Hong Kong, China; (J.H.); (Z.C.); (S.-W.P.); (J.H.C.L.)
| | - Zilin Chen
- Department of Biomedical Engineering, City University of Hong Kong, Hong Kong, China; (J.H.); (Z.C.); (S.-W.P.); (J.H.C.L.)
| | - Se-Weon Park
- Department of Biomedical Engineering, City University of Hong Kong, Hong Kong, China; (J.H.); (Z.C.); (S.-W.P.); (J.H.C.L.)
- Hong Kong Centre for Cerebro-Cardiovascular Health Engineering (COCHE), Hong Kong, China
| | - Joseph H. C. Lai
- Department of Biomedical Engineering, City University of Hong Kong, Hong Kong, China; (J.H.); (Z.C.); (S.-W.P.); (J.H.C.L.)
| | - Kannie W. Y. Chan
- Department of Biomedical Engineering, City University of Hong Kong, Hong Kong, China; (J.H.); (Z.C.); (S.-W.P.); (J.H.C.L.)
- Hong Kong Centre for Cerebro-Cardiovascular Health Engineering (COCHE), Hong Kong, China
- Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
- Shenzhen Research Institute, City University of Hong Kong, Shenzhen 518057, China
- Tung Biomedical Science Centre, City University of Hong Kong, Hong Kong, China
| |
Collapse
|
30
|
Di Girolamo M, Grossi A. Contrast agents for MRI and side effects. Nucl Med Mol Imaging 2022. [DOI: 10.1016/b978-0-12-822960-6.00094-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
|
31
|
Ludewig P, Graeser M, Forkert ND, Thieben F, Rández-Garbayo J, Rieckhoff J, Lessmann K, Förger F, Szwargulski P, Magnus T, Knopp T. Magnetic particle imaging for assessment of cerebral perfusion and ischemia. WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY 2021; 14:e1757. [PMID: 34617413 DOI: 10.1002/wnan.1757] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/08/2021] [Revised: 08/30/2021] [Accepted: 09/03/2021] [Indexed: 02/04/2023]
Abstract
Stroke is one of the leading worldwide causes of death and sustained disability. Rapid and accurate assessment of cerebral perfusion is essential to diagnose and successfully treat stroke patients. Magnetic particle imaging (MPI) is a new technology with the potential to overcome some limitations of established imaging modalities. It is an innovative and radiation-free imaging technique with high sensitivity, specificity, and superior temporal resolution. MPI enables imaging and diagnosis of stroke and other neurological pathologies such as hemorrhage, tumors, and inflammatory processes. MPI scanners also offer the potential for targeted therapies of these diseases. Due to lower field requirements, MPI scanners can be designed as resistive magnets and employed as mobile devices for bedside imaging. With these advantages, MPI could accelerate and improve the diagnosis and treatment of neurological disorders. This review provides a basic introduction to MPI, discusses its current use for stroke imaging, and addresses future applications, including the potential for clinical implementation. This article is categorized under: Diagnostic Tools > In Vivo Nanodiagnostics and Imaging Therapeutic Approaches and Drug Discovery > Nanomedicine for Neurological Disease.
Collapse
Affiliation(s)
- Peter Ludewig
- Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Matthias Graeser
- Section for Biomedical Imaging at the University Medical Center Hamburg-Eppendorf, Hamburg, Germany.,Institute for Biomedical Imaging, Hamburg University of Technology, Hamburg, Germany.,Fraunhofer Research Institute for Individualized and Cell-based Medicine, Lübeck, Germany.,Institute for Medical Engineering, University of Lübeck, Lübeck, Germany
| | - Nils D Forkert
- Department of Radiology and Hotchkiss Brain Institute, University of Calgary, Calgary, Canada
| | - Florian Thieben
- Section for Biomedical Imaging at the University Medical Center Hamburg-Eppendorf, Hamburg, Germany.,Institute for Biomedical Imaging, Hamburg University of Technology, Hamburg, Germany
| | - Javier Rández-Garbayo
- Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Johanna Rieckhoff
- Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Katrin Lessmann
- Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Fynn Förger
- Section for Biomedical Imaging at the University Medical Center Hamburg-Eppendorf, Hamburg, Germany.,Institute for Biomedical Imaging, Hamburg University of Technology, Hamburg, Germany
| | - Patryk Szwargulski
- Section for Biomedical Imaging at the University Medical Center Hamburg-Eppendorf, Hamburg, Germany.,Institute for Biomedical Imaging, Hamburg University of Technology, Hamburg, Germany
| | - Tim Magnus
- Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Tobias Knopp
- Section for Biomedical Imaging at the University Medical Center Hamburg-Eppendorf, Hamburg, Germany.,Institute for Biomedical Imaging, Hamburg University of Technology, Hamburg, Germany
| |
Collapse
|
32
|
Jiang C, Li J, Huang Y, Huang D, Lin J, Jiang X. Clinical safety evaluation of contrast agents based on real-world evidence. J Clin Pharm Ther 2021; 46:1600-1605. [PMID: 34293194 DOI: 10.1111/jcpt.13485] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2021] [Revised: 06/22/2021] [Accepted: 06/29/2021] [Indexed: 11/30/2022]
Abstract
WHAT IS KNOWN AND OBJECTIVE This study was aimed at comparing the adverse drug reactions (ADRs) arising from the use of iodinated contrast medium (ICM) and gadolinium-based contrast media (GBCM), and to provide a basis for the clinical selection of contrast media. METHODS Retrospective data for ADR cases occurring from the use of ICM or GBCM during enhanced scanning in computed tomography and magnetic resonance imaging were collected between June/2013 and May/2020 from Wenling Hospital of Traditional Chinese Medicine. Chi-square tests were performed based on the characteristics of patients and the classification of contrast medium. Bonferroni correction was applied to the statistical analyses with multiple comparisons of proportions. RESULTS Among 27,328 patients who were subjected to enhanced CT scanning, 207 cases (0.76%) showed ICM-related ADRs. Among 16,381 patients who were subjected to enhanced MRI scanning, 25 cases (0.15%) showed ADRs related to GBCM. The incidence of ADR induced by GBCM was significantly lower than ICM-induced ADR (p < 0.01). There were no significant differences in the incidence among different types of ICM, including ioversol and iodixanol, as well as iodixanol from different manufacturers (p > 0.05). Interestingly, the ADR incidence of ICM seemed to be associated with gender, with a significantly higher incidence in females than in male patients, and it was also associated with the age, with a lower occurrence in older (>44 years) compared to younger patients. WHAT IS NEW AND CONCLUSION With respect to ADR incidence, the safety profile of ICM of different types and different manufacturers was found to be similar in clinical use, warranting no need of specifically choosing imported or more expensive products. While choosing contrast medium type for clinical use, attention should be paid to certain populations, especially to younger and female patients when the patients are about to undergo a contrast-enhanced examination.
Collapse
Affiliation(s)
- Cheng Jiang
- Department of Pharmacy, Tongde Hospital of Zhejiang Province, Hangzhou, China
| | - Junlian Li
- Endoscopy Center, Wenling Hospital of Traditional Chinese Medicine Affiliated to Zhejiang University of Traditional Chinese Medicine, Wenling, China
| | - Yaoqin Huang
- Department of Pharmacy, Wenling Hospital of Traditional Chinese Medicine Affiliated to Zhejiang University of Traditional Chinese Medicine, Wenling, China
| | - Daiying Huang
- Wenling Adverse Drug Reaction Monitoring Center, Wenling, China
| | - Jingran Lin
- School of Medicine, Zhejiang University, Hangzhou, China
| | - Xin Jiang
- Department of Pharmacy, Wenling Hospital of Traditional Chinese Medicine Affiliated to Zhejiang University of Traditional Chinese Medicine, Wenling, China
| |
Collapse
|
33
|
Khalighinejad P, Parrott D, Clavijo Jordan V, Chirayil S, Preihs C, Rofsky NM, Xi Y, Sherry AD. Magnetic Resonance Imaging Detection of Glucose-Stimulated Zinc Secretion in the Enlarged Dog Prostate as a Potential Method for Differentiating Prostate Cancer From Benign Prostatic Hyperplasia. Invest Radiol 2021; 56:450-457. [PMID: 34086013 PMCID: PMC10042468 DOI: 10.1097/rli.0000000000000760] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
OBJECTIVES In the United States, prostate cancer (PCa) is the most common cancer in men. Multi-parametric magnetic resonance imaging (MRI) is increasingly being relied upon for the diagnosis and characterization of PCa, but differentiating malignancy from benign prostatic hyperplasia (BPH) in the transition zone using MRI can be challenging. The characteristically high levels of zinc in human prostate tissue and a close relationship between malignant proliferation and zinc homeostatic dysregulation create opportunities to visualize PCa with novel contrast media. In mouse models, glucose-stimulated zinc secretion (GSZS) can be preferentially observed in healthy prostate tissue compared with malignant tissue; in vivo, these differences can be captured with MRI by using Gdl1, a gadolinium-based zinc-responsive contrast agent. In this study, we examined whether this technology can be applied in a large animal model by imaging older dogs with clinically diagnosed BPH. MATERIALS AND METHODS Four intact male dogs 6 years or older with enlarged prostates were imaged (T1-weighted turbo spin-echo, TE/TR, 12/400 milliseconds and T2-weighted, TE/TR, 112/5000 milliseconds) using a 3 T scanner before and at multiple time points after intravenous injection of 0.05 mmol/kg GdL1 plus either (a) 2 mL/kg of 50% dextrose in 1 session or (b) 2 mL/kg normal saline in another session. The two sessions were one week apart, and their order was randomly determined for each dog. During postprocessing, regions of interest were generated in prostate tissue and in paraspinal muscles to evaluate the contrast-to-noise ratio (CNR). The ratio of CNR at any postinjection time point compared with baseline CNR was defined as r-CNR. After the second imaging session, the dogs were euthanized, and their prostates were harvested for histopathological examination. Baseline and postintervention plasma and urine samples were analyzed for total zinc by inductively coupled plasma mass spectrometry. RESULTS The mean ± SD r-CNR values at 13 minutes postinjection in the dextrose versus saline imaging sessions were 134% ± 10% and 127% ± 7%, respectively (P < 0.01). The histopathologic evaluation of prostate tissues confirmed BPH in all dogs. Interestingly, prostatic intraepithelial neoplasia was detected in 1 animal, and a suspicious mass was found in the same region on T2-weighted scans. The r-CNR of the mass was calculated as 113% ± 4% and 111% ± 6% in the dextrose and saline groups, respectively, with no significant differences between the 2 interventions (P = 0.54), whereas there was a statistically significant difference between the r-CNR of the whole prostate in the dextrose (130% ±11%) and saline (125% ± 9%) interventions (P = 0.03). Inductively coupled plasma mass spectrometry analyses showed a significantly higher urinary zinc in the dextrose versus saline groups, but no differences were found in plasma zinc levels. CONCLUSIONS T1-weighted MRI of the enlarged canine prostate showed higher r-CNR after injection of GdL1 plus dextrose compared with GdL1 plus saline, consistent with GSZS from BPH tissues. One small region of neoplastic tissue was identified in a single dog on the basis of less GSZS from that region by MRI. These findings suggest a new method for the detection of PCa by MRI that could facilitate the differentiation of BPH from PCa in the transition zone.
Collapse
Affiliation(s)
- Pooyan Khalighinejad
- Advanced Imaging Research Center, University of Texas Southwestern Medical Center, Dallas
| | - Daniel Parrott
- Advanced Imaging Research Center, University of Texas Southwestern Medical Center, Dallas
- Department of Radiology, University of Texas Southwestern Medical Center, Dallas
| | - Veronica Clavijo Jordan
- Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital/Harvard Medical School, Charlestown; VitalQuan, LLC, Dallas, TX
| | - Sara Chirayil
- Advanced Imaging Research Center, University of Texas Southwestern Medical Center, Dallas
| | - Christian Preihs
- Advanced Imaging Research Center, University of Texas Southwestern Medical Center, Dallas
- Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital/Harvard Medical School, Charlestown; VitalQuan, LLC, Dallas, TX
| | - Neil M. Rofsky
- Advanced Imaging Research Center, University of Texas Southwestern Medical Center, Dallas
- Department of Radiology, University of Texas Southwestern Medical Center, Dallas
| | - Yin Xi
- Department of Radiology, University of Texas Southwestern Medical Center, Dallas
| | - A. Dean Sherry
- Advanced Imaging Research Center, University of Texas Southwestern Medical Center, Dallas
- Department of Radiology, University of Texas Southwestern Medical Center, Dallas
- Department of Chemistry & Biochemistry, the University of Texas at Dallas, Richardson
| |
Collapse
|
34
|
Ian Paterson D, White JA, Butler CR, Connelly KA, Guerra PG, Hill MD, James MT, Kirpalani A, Lydell CP, Roifman I, Sarak B, Sterns LD, Verma A, Wan D, Crean AM, Grosse-Wortmann L, Hanneman K, Leipsic J, Manlucu J, Nguyen ET, Sandhu RK, Villemaire C, Wald RM, Windram J. 2021 Update on Safety of Magnetic Resonance Imaging: Joint Statement From Canadian Cardiovascular Society/Canadian Society for Cardiovascular Magnetic Resonance/Canadian Heart Rhythm Society. Can J Cardiol 2021; 37:835-847. [PMID: 34154798 DOI: 10.1016/j.cjca.2021.02.012] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2020] [Revised: 02/15/2021] [Accepted: 02/18/2021] [Indexed: 11/30/2022] Open
Abstract
Magnetic resonance imaging (MRI) is often considered the gold-standard test for characterizing cardiac as well as noncardiac structure and function. However, many patients with cardiac implantable electronic devices (CIEDs) and/or severe renal dysfunction are unable to undergo this test because of safety concerns. In the past 10 years, newer-generation CIEDs and gadolinium-based contrast agents (GBCAs) as well as coordinated care between imaging and heart rhythm device teams have mitigated risk to patients and improved access to MRI at many hospitals. The purpose of this statement is to review published data on safety of MRI in patients with conditional and nonconditional CIEDs in addition to patient risks from older and newer GBCAs. This statement was developed through multidisciplinary collaboration of pan-Canadian experts after a relevant and independent literature search by the Canadian Agency for Drugs and Technologies in Health. All recommendations align with the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system. Key recommendations include: (1) the development of standardized protocols for patients with a CIED undergoing MRI; (2) patients with MRI nonconditional pacemakers and pacemaker dependency should be programmed to asynchronous mode and those with MRI nonconditional transvenous defibrillators should have tachycardia therapies turned off during the scan; and (3) macrocyclic or newer linear GBCAs should be used in preference to older GBCAs because of their better safety profile in patients at higher risk of nephrogenic systemic fibrosis.
Collapse
Affiliation(s)
| | - D Ian Paterson
- Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, Alberta, Canada.
| | - James A White
- Calgary Foothills Medical Centre, University of Calgary, Calgary, Alberta, Canada
| | - Craig R Butler
- Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, Alberta, Canada
| | - Kim A Connelly
- St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada
| | - Peter G Guerra
- Institut de Cardiologie de Montréal, Université de Montréal, Montréal, Québec, Canada
| | - Michael D Hill
- Calgary Foothills Medical Centre, University of Calgary, Calgary, Alberta, Canada
| | - Matthew T James
- Calgary Foothills Medical Centre, University of Calgary, Calgary, Alberta, Canada
| | - Anish Kirpalani
- St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada
| | - Carmen P Lydell
- Calgary Foothills Medical Centre, University of Calgary, Calgary, Alberta, Canada
| | - Idan Roifman
- Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
| | - Bradley Sarak
- St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada
| | - Laurence D Sterns
- Royal Jubilee Hospital, University of British Columbia, Victoria, British Columbia, Canada
| | - Atul Verma
- Southlake Regional Health Centre, Newmarket, Ontario, Canada
| | - Douglas Wan
- Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
| | | | - Andrew M Crean
- Ottawa Heart Institute, University of Ottawa, Ottawa, Ontario, Canada
| | - Lars Grosse-Wortmann
- Doernbecher Children's Hospital, Oregon Health and Science University, Portland, Oregon, USA
| | - Kate Hanneman
- Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada
| | - Jonathon Leipsic
- St Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada
| | - Jaimie Manlucu
- London Health Sciences Centre, Western University, London, Ontario, Canada
| | - Elsie T Nguyen
- Doernbecher Children's Hospital, Oregon Health and Science University, Portland, Oregon, USA
| | - Roopinder K Sandhu
- Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, Alberta, Canada
| | - Christine Villemaire
- Institut de Cardiologie de Montréal, Université de Montréal, Montréal, Québec, Canada
| | - Rachel M Wald
- Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada
| | - Jonathan Windram
- Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, Alberta, Canada
| |
Collapse
|
35
|
Walker D, McGrath TA, Glikstein R, Chakraborty S, Blanchette C, Schieda N. Empiric Switching of Gadolinium-Based Contrast Agents in Patients With History of Previous Immediate Hypersensitivity Reaction to GBCA: A Prospective Single-Center, Single-Arm Efficacy Trial. Invest Radiol 2021; 56:369-373. [PMID: 33337738 DOI: 10.1097/rli.0000000000000750] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
BACKGROUND Breakthrough hypersensitivity reactions (HRs) to gadolinium-based contrast agent (GBCA) occur in 40% of patients despite corticosteroid premedication. Other strategies to reduce HRs are not well studied. OBJECTIVE The aim of this study was to prospectively evaluate HR rate to GBCA among patients with history of HR to GBCA, empirically given an alternative GBCA prior to repeat administration. MATERIALS AND METHODS From September 2019 to September 2020, patients with prior HR to GBCA received 13-hour oral corticosteroid and diphenhydramine premedication prescription with switching of GBCA to gadoterate (previously unavailable at our institution before September 2019). Power analysis (α error, 0.05; β error, 0.80) determined 21 patients were required. Patients were evaluated under a quality assurance waiver from the institutional review board. A radiologist documented the nature of initial HR and inciting GBCA, premedication received, incidence, and severity of breakthrough HR. RESULTS After exclusions, we evaluated 26 patients with mild (92.3% [24/26]) or moderate (7.7% [2/26]) HR to gadobutrol (53.8% [14/26]), gadoxetate (3.8% [1/26]), and gadopentetate (3.8% [1/26]). In 38.5% (10/26), inciting GBCA was unknown but was likely gadobutrol or gadopentetate based on availability. There were 22 females. The mean patient age was 52.1 ± 15.8 years.From 27 gadoterate administrations, 59.3% (16/27) patients received corticosteroid and diphenhydramine premedication, 11.1% (3/27) received only diphenhydramine, and 29.6% (8/27) with no premedication.Hypersensitivity reaction rate after empiric switching to gadoterate was 3.7% (1 mild reaction; 95% confidence interval [CI], 0.09%-18.9%) overall with no difference in patients with (6.3% [1/16]; 95% CI, 0.15%-28.7%) or without (0%; [0/11] upper bound 95% CI, 25.0%) corticosteroid premedication. CONCLUSIONS In this prospective single-arm study, empirically switching GBCA to gadoterate in patients with prior HR to GBCA substantially reduced the expected rate of subsequent HRs in patients with and without the use of corticosteroid premedication. IMPLICATIONS FOR PATIENT CARE Empirically switching GBCAs, with or without the use of corticosteroid premedication, can substantially reduce the rate of hypersensitivity breakthrough reactions.
Collapse
Affiliation(s)
- Daniel Walker
- From the Department of Medical Imaging, The Ottawa Hospital, Ottawa, Ontario, Canada
| | | | | | | | | | | |
Collapse
|
36
|
Woolen SA, Troost JP, Khalatbari S, Pujara AC, McDonald JS, McDonald RJ, Shankar P, Lewin AA, Melsaether AN, Westphal SM, Patterson KH, Nettles A, Welby JP, Patel PP, Kiros N, Piccoli L, Davenport MS. Prospective multicenter assessment of patient preferences for properties of gadolinium-based contrast media and their potential socioeconomic impact in a screening breast MRI setting. Eur Radiol 2021; 31:9139-9149. [PMID: 34047845 PMCID: PMC8160413 DOI: 10.1007/s00330-021-07982-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2020] [Revised: 02/19/2021] [Accepted: 04/01/2021] [Indexed: 12/01/2022]
Abstract
Objective It is unknown how patients prioritize gadolinium-based contrast media (GBCM) benefits (detection sensitivity) and risks (reactions, gadolinium retention, cost). The purpose of this study is to measure preferences for properties of GBCM in women at intermediate or high risk of breast cancer undergoing annual screening MRI. Methods An institutional reviewed board-approved prospective discrete choice conjoint survey was administered to patients at intermediate or high risk for breast cancer undergoing screening MRI at 4 institutions (July 2018–March 2020). Participants were given 15 tasks and asked to choose which of two hypothetical GBCM they would prefer. GBCMs varied by the following attributes: sensitivity for cancer detection (80–95%), intracranial gadolinium retention (1–100 molecules per 100 million administered), severe allergic-like reaction rate (1–19 per 100,000 administrations), mild allergic-like reaction rate (10–1000 per 100,000 administrations), out-of-pocket cost ($25–$100). Attribute levels were based on published values of existing GBCMs. Hierarchical Bayesian analysis was used to derive attribute “importance.” Preference shares were determined by simulation. Results Response (87% [247/284]) and completion (96% [236/247]) rates were excellent. Sensitivity (importance = 44.3%, 95% confidence interval = 42.0–46.7%) was valued more than GBCM-related risks (mild allergic-like reaction risk (19.5%, 17.9–21.1%), severe allergic-like reaction risk (17.0%, 15.8–18.1%), intracranial gadolinium retention (11.6%, 10.5–12.7%), out-of-pocket expense (7.5%, 6.8–8.3%)). Lower income participants placed more importance on cost and less on sensitivity (p < 0.01). A simulator is provided that models GBCM preference shares by GBCM attributes and competition. Conclusions Patients at intermediate or high risk for breast cancer undergoing MRI screening prioritize cancer detection over GBCM-related risks, and prioritize reaction risks over gadolinium retention. Key Points • Among women undergoing annual breast MRI screening, cancer detection sensitivity (attribute “importance,” 44.3%) was valued more than GBCM-related risks (mild allergic reaction risk 19.5%, severe allergic reaction risk 17.0%, intracranial gadolinium retention 11.6%, out-of-pocket expense 7.5%). • Prospective four-center patient preference data have been incorporated into a GBCM choice simulator that allows users to input GBCM properties and calculate patient preference shares for competitor GBCMs. • Lower-income women placed more importance on out-of-pocket cost and less importance on cancer detection (p < 0.01) when prioritizing GBCM properties. Supplementary Information The online version contains supplementary material available at 10.1007/s00330-021-07982-y.
Collapse
Affiliation(s)
- Sean A Woolen
- Department of Radiology and Biomedical Imaging, UCSF, 350 Parnassus, San Francisco, CA, 94117, USA.
| | - Jonathan P Troost
- Michigan Institute for Clinical & Health Research, Michigan Medicine, Ann Arbor, MI, USA
| | - Shokoufeh Khalatbari
- Michigan Institute for Clinical & Health Research, Michigan Medicine, Ann Arbor, MI, USA
| | - Akshat C Pujara
- Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, GA, USA
| | | | | | - Prasad Shankar
- Department of Radiology, Michigan Medicine, Ann Arbor, MI, USA
- Michigan Radiology Quality Collaborative, Michigan Medicine, Ann Arbor, MI, USA
| | - Alana A Lewin
- Department of Radiology, Center for Biomedical Imaging, New York University School of Medicine, New York, NY, USA
| | | | - Steven M Westphal
- Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN, USA
| | - Katherine H Patterson
- Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN, USA
| | - Ashley Nettles
- Department of Radiology, Michigan Medicine, Ann Arbor, MI, USA
| | - John P Welby
- Department of Radiology, Mayo Clinic, Rochester, MN, USA
| | | | - Neud Kiros
- Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN, USA
| | - Lisa Piccoli
- Department of Radiology, Center for Biomedical Imaging, New York University School of Medicine, New York, NY, USA
| | - Matthew S Davenport
- Department of Radiology, Michigan Medicine, Ann Arbor, MI, USA
- Michigan Radiology Quality Collaborative, Michigan Medicine, Ann Arbor, MI, USA
| |
Collapse
|
37
|
Benzon HT, Maus TP, Kang HR, Provenzano DA, Bhatia A, Diehn F, Nelson A, McCormick ZL, Liu BP, de Andres Ares J, Anitescu M, Blackham K, Bhaskar A, Brill S, Collins J, Gulve A, Hurley RW, Jeon YH, Moon JY, Rauck RL, Rodes M, Lee RK, Shah V, Shanthanna H, van Zundert J, Huntoon M, Rathmell JP, Borges MS, Cohen SP, Greenberger PA. The Use of Contrast Agents in Interventional Pain Procedures: A Multispecialty and Multisociety Practice Advisory on Nephrogenic Systemic Fibrosis, Gadolinium Deposition in the Brain, Encephalopathy After Unintentional Intrathecal Gadolinium Injection, and Hypersensitivity Reactions. Anesth Analg 2021; 133:535-552. [PMID: 33755647 DOI: 10.1213/ane.0000000000005443] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
This Practice Advisory presents a comprehensive and evidence-based set of position statements and recommendations for the use of contrast media in interventional pain procedures. The advisory was established by an international panel of experts under the auspices of 11 multinational and multispecialty organizations based on a comprehensive review of the literature up to December 31, 2019. The advisory discusses the risks of using gadolinium-based contrast agents. These include nephrogenic systemic fibrosis, gadolinium brain deposition/retention, and encephalopathy and death after an unintentional intrathecal gadolinium injection. The advisory provides recommendations on the selection of a specific gadolinium-based contrast agent in patients with renal insufficiency, those who had multiple gadolinium-enhanced magnetic resonance imaging examinations, and in cases of paraspinal injections. Additionally, recommendations are made for patients who have a history of mild, moderate, or severe hypersensitivity reactions to contrast medium.
Collapse
Affiliation(s)
- Honorio T Benzon
- From the Department of Anesthesiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois
| | - Timothy P Maus
- Department of Radiology, Mayo Clinic, Rochester, Minnesota
| | - Hye-Ryun Kang
- Department of Medicine (Allergy and Immunology), Seoul National University, Seoul, South Korea
| | | | - Anuj Bhatia
- Department of Anesthesiology, University of Toronto, Toronto, Ontario, Canada
| | - Felix Diehn
- Department of Radiology, Mayo Clinic, Rochester, Minnesota
| | - Ariana Nelson
- Department of Anesthesiology, University of California at Irvine, Irvine, California
| | - Zachary L McCormick
- Department of Physical Medicine and Rehabilitation, University of Utah, Salt Lake City, Utah
| | - Benjamin P Liu
- Department of Radiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois
| | | | | | - Kristine Blackham
- Department of Radiology, University Hospital, Basel, Basel, Switzerland
| | - Arun Bhaskar
- Imperial College Healthcare NHS Trust, London, United Kingdom
| | - Silviu Brill
- Institute of Pain Medicine, Tel Aviv Medical Centre, Tel Aviv, Israel
| | - Jeremy Collins
- Department of Radiology, Mayo Clinic, Rochester, Minnesota
| | - Ashish Gulve
- Department of Pain Management, James Cook University Hospital, Middlesbrough, United Kingdom
| | - Robert W Hurley
- Department of Anesthesiology, Wake Forest School of Medicine, Winston-Salem, North Carolina
| | - Young Hoon Jeon
- Anesthesiology and Pain Medicine, School of Dentistry, Kyungpook National University, Daegu, South Korea
| | - Jee Youn Moon
- Department of Anesthesiology, Seoul National University, Seoul, South Korea
| | | | - Meghan Rodes
- From the Department of Anesthesiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois
| | - Ryan K Lee
- Department of Radiology, Sydney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania
| | - Vinil Shah
- Department of Radiology, University of California at San Francisco, San Francisco, California
| | - Harsha Shanthanna
- Department of Anesthesiology, McMaster University, Hamilton, Ontario, Canada
| | - Jan van Zundert
- Anesthesiology and Pain Medicine, Maastricht University Medical Center, Maastricht, the Netherlands
| | - Marc Huntoon
- Department of Anesthesiology, Virginia Commonwealth University, Medical College of Virginia, Richmond, Virginia
| | - James P Rathmell
- Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Boston, Massachusetts
| | - Mario Sanchez Borges
- Department of Allergy and Clinical Immunology, Centro Medico Docente La Trinidad, Caracas, Venezuela
| | - Steven P Cohen
- Department of Anesthesiology and Critical Care Medicine, Pain Medicine Division, Department of Physical Medicine and Rehabilitation, and Department of Neurology, and Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore, Maryland
| | - Paul A Greenberger
- Department of Medicine, Division of Allergy and Immunology, Northwestern University Feinberg School of Medicine, Chicago, Illinois
| |
Collapse
|
38
|
Nucera E, Urbani S, Buonomo A, De Pasquale T, Rizzi A, Aruanno A, Pucci S. Gadolinium-Based Contrast Agents Hypersensitivity: A Case Series. J Asthma Allergy 2021; 14:241-244. [PMID: 33758514 PMCID: PMC7979346 DOI: 10.2147/jaa.s295748] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2020] [Accepted: 01/26/2021] [Indexed: 11/24/2022] Open
Abstract
Gadolinium-based contrast agents (GBCAs) are considered to be safe, although sometimes patients report a hypersensitivity reaction when undergoing magnetic resonance imaging (MRI). The mechanisms of these reactions and of the sensitization to GBCAs are still largely unknown. We describe four cases of patients who experienced immediate adverse reactions to GBCAs with a demonstrated cutaneous hypersensitivity suggesting an IgE-mediated mechanism.
Collapse
Affiliation(s)
- Eleonora Nucera
- Allergy Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
| | - Sara Urbani
- Allergy Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
| | - Alessandro Buonomo
- Allergy Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
| | | | - Angela Rizzi
- Allergy Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
| | - Arianna Aruanno
- Allergy Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
| | - Stefano Pucci
- Civitanova Marche Hospital, Civitanova Marche, Italy
| |
Collapse
|
39
|
Klostranec JM, Rohringer T, Gerber R, Murphy KJ. The Role of Biologic Sex in Anaphylactoid Contrast Reactions: An Important Consideration for Women of Reproductive Age and Undergoing Hormone Replacement Therapy. Radiology 2021; 299:272-275. [PMID: 33656392 DOI: 10.1148/radiol.2021203516] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Jesse M Klostranec
- From the Department of Medical Imaging, University of Toronto, Toronto, Canada; and Division of Neuroradiology, Toronto Western Hospital, University Health Network, 399 Bathurst St, Toronto, ON, Canada M5T 2S8
| | - Taryn Rohringer
- From the Department of Medical Imaging, University of Toronto, Toronto, Canada; and Division of Neuroradiology, Toronto Western Hospital, University Health Network, 399 Bathurst St, Toronto, ON, Canada M5T 2S8
| | - Rachel Gerber
- From the Department of Medical Imaging, University of Toronto, Toronto, Canada; and Division of Neuroradiology, Toronto Western Hospital, University Health Network, 399 Bathurst St, Toronto, ON, Canada M5T 2S8
| | - Kieran J Murphy
- From the Department of Medical Imaging, University of Toronto, Toronto, Canada; and Division of Neuroradiology, Toronto Western Hospital, University Health Network, 399 Bathurst St, Toronto, ON, Canada M5T 2S8
| |
Collapse
|
40
|
Bustamante M, Viola F, Carlhäll CJ, Ebbers T. Using Deep Learning to Emulate the Use of an External Contrast Agent in Cardiovascular 4D Flow MRI. J Magn Reson Imaging 2021; 54:777-786. [PMID: 33629795 DOI: 10.1002/jmri.27578] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2020] [Revised: 02/04/2021] [Accepted: 02/13/2021] [Indexed: 11/08/2022] Open
Abstract
BACKGROUND Although contrast agents would be beneficial, they are seldom used in four-dimensional (4D) flow magnetic resonance imaging (MRI) due to potential side effects and contraindications. PURPOSE To develop and evaluate a deep learning architecture to generate high blood-tissue contrast in noncontrast 4D flow MRI by emulating the use of an external contrast agent. STUDY TYPE Retrospective. SUBJECTS Of 222 data sets, 141 were used for neural network (NN) training (69 with and 72 without contrast agent). Evaluation was performed on the remaining 81 noncontrast data sets. FIELD STRENGTH/SEQUENCES Gradient echo or echo-planar 4D flow MRI at 1.5 T and 3 T. ASSESSMENT A cyclic generative adversarial NN was trained to perform image translation between noncontrast and contrast data. Evaluation was performed quantitatively using contrast-to-noise ratio (CNR), signal-to-noise ratio (SNR), structural similarity index (SSIM), mean squared error (MSE) of edges, and Dice coefficient of segmentations. Three observers performed a qualitative assessment of blood-tissue contrast, noise, presence of artifacts, and image structure visualization. STATISTICAL TESTS The Wilcoxon rank-sum test evaluated statistical significance. Kendall's concordance coefficient assessed interobserver agreement. RESULTS Contrast in the regions of interest (ROIs) in the NN enhanced images increased by 88%, CNR increased by 63%, and SNR improved by 48% (all P < 0.001). The SSIM was 0.82 ± 0.01, and the MSE of edges was 0.09 ± 0.01 (range [0,1]). Segmentations based on the generated images resulted in a Dice similarity increase of 15.25%. The observers managed to differentiate between contrast MR images and our results; however, they preferred the NN enhanced images in 76.7% of cases. This percentage increased to 93.3% for phase-contrast MR angiograms created from the NN enhanced data. Visual grading scores were blood-tissue contrast = 4.30 ± 0.74, noise = 3.12 ± 0.98, and presence of artifacts = 3.63 ± 0.76. Image structures within and without the ROIs resulted in scores of 3.42 ± 0.59 and 3.07 ± 0.71, respectively (P < 0.001). DATA CONCLUSION The proposed approach improves blood-tissue contrast in MR images and could be used to improve data quality, visualization, and postprocessing of cardiovascular 4D flow data. EVIDENCE LEVEL: 3 TECHNICAL EFFICACY: Stage 1.
Collapse
Affiliation(s)
- Mariana Bustamante
- Division of Diagnostics and Specialist Medicine, Department of Health Medicine and Caring Sciences, Linköping University, Linköping, Sweden.,Center for Medical Image Science and Visualization (CMIV), Linköping University, Linköping, Sweden
| | - Federica Viola
- Division of Diagnostics and Specialist Medicine, Department of Health Medicine and Caring Sciences, Linköping University, Linköping, Sweden
| | - Carl-Johan Carlhäll
- Division of Diagnostics and Specialist Medicine, Department of Health Medicine and Caring Sciences, Linköping University, Linköping, Sweden.,Center for Medical Image Science and Visualization (CMIV), Linköping University, Linköping, Sweden.,Department of Clinical Physiology in Linköping and Department of Health Medicine and Caring Sciences, Linköping University, Linköping, Sweden
| | - Tino Ebbers
- Division of Diagnostics and Specialist Medicine, Department of Health Medicine and Caring Sciences, Linköping University, Linköping, Sweden.,Center for Medical Image Science and Visualization (CMIV), Linköping University, Linköping, Sweden
| |
Collapse
|
41
|
Bäuerle T, Saake M, Uder M. Gadolinium-based contrast agents: What we learned from acute adverse events, nephrogenic systemic fibrosis and brain retention. ROFO-FORTSCHR RONTG 2020; 193:1010-1018. [PMID: 33348385 DOI: 10.1055/a-1328-3177] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
BACKGROUND Radiologists have been administering gadolinium-based contrast agents (GBCA) in magnetic resonance imaging for several decades, so that there is abundant experience with these agents regarding allergic-like reactions, nephrogenic systemic fibrosis (NSF) and gadolinium retention in the brain. METHODS This review is based on a selective literature search and reflects the current state of research on acute adverse effects of GBCA, NSF and brain retention of gadolinium. RESULTS Due to the frequent use of GBCA, data on adverse effects of these compounds are available in large collectives. Allergic-like reactions occurred rarely, whereas severe acute reactions were very rarely observed. Systemic changes in NSF also occur very rarely, although measures to avoid NSF resulted in a significantly reduced incidence of NSF. Due to gadolinium retention in the body after administration of linear MR contrast agents, only macrocyclic preparations are currently used with few exceptions. Clear clinical correlates of gadolinium retention in the brain could not be identified so far. Although the clinical added value of GBCA is undisputed, individual risks associated with the injection of GBCA should be identified and the use of non-contrast enhanced MR techniques should be considered. Alternative contrast agents such as iron oxide nanoparticles are not clinically approved, but are currently undergoing clinical trials. CONCLUSION GBCA have a very good risk profile with a low rate of adverse effects or systemic manifestations such as NSF. Gadolinium retention in the brain can be minimized by the use of macrocyclic GBCA, although clear clinical correlates due to gadolinium retention in the brain following administration of linear GBCA could not be identified yet. KEY POINTS · Acute adverse effects are predominantly mild/moderate, rarely severe reactions occur.. · International guidelines resulted in significant reduction of nephrogenic systemic fibrosis.. · Application of macrocyclic contrast agents minimizes gadolinium retention in the brain.. CITATION FORMAT · Bäuerle T, Saake M, Uder M. Gadolinium-based contrast agents: What we learned from acute adverse events, nephrogenic systemic fibrosis and brain retention. Fortschr Röntgenstr 2021; 193: 1010 - 1018.
Collapse
Affiliation(s)
- Tobias Bäuerle
- Institute of Radiology, University Medical Center, Erlangen, Germany
| | - Marc Saake
- Institute of Radiology, University Medical Center, Erlangen, Germany
| | - Michael Uder
- Institute of Radiology, University Medical Center, Erlangen, Germany
| |
Collapse
|
42
|
Kader A, Brangsch J, Kaufmann JO, Zhao J, Mangarova DB, Moeckel J, Adams LC, Sack I, Taupitz M, Hamm B, Makowski MR. Molecular MR Imaging of Prostate Cancer. Biomedicines 2020; 9:1. [PMID: 33375045 PMCID: PMC7822017 DOI: 10.3390/biomedicines9010001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2020] [Revised: 12/18/2020] [Accepted: 12/19/2020] [Indexed: 02/06/2023] Open
Abstract
This review summarizes recent developments regarding molecular imaging markers for magnetic resonance imaging (MRI) of prostate cancer (PCa). Currently, the clinical standard includes MR imaging using unspecific gadolinium-based contrast agents. Specific molecular probes for the diagnosis of PCa could improve the molecular characterization of the tumor in a non-invasive examination. Furthermore, molecular probes could enable targeted therapies to suppress tumor growth or reduce the tumor size.
Collapse
Affiliation(s)
- Avan Kader
- Department of Radiology, Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Charitéplatz 1, 10117 Berlin, Germany; (J.B.); (J.O.K.); (J.Z.); (D.B.M.); (J.M.); (L.C.A.); (I.S.); (M.T.); (B.H.); (M.R.M.)
- Department of Biology, Chemistry and Pharmacy, Institute of Biology, Freie Universität Berlin, Königin-Luise-Str. 1-3, 14195 Berlin, Germany
| | - Julia Brangsch
- Department of Radiology, Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Charitéplatz 1, 10117 Berlin, Germany; (J.B.); (J.O.K.); (J.Z.); (D.B.M.); (J.M.); (L.C.A.); (I.S.); (M.T.); (B.H.); (M.R.M.)
- Department of Veterinary Medicine, Institute of Animal Welfare, Animal Behavior and Laboratory Animal Science, Freie Universität Berlin, Königsweg 67, Building 21, 14163 Berlin, Germany
| | - Jan O. Kaufmann
- Department of Radiology, Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Charitéplatz 1, 10117 Berlin, Germany; (J.B.); (J.O.K.); (J.Z.); (D.B.M.); (J.M.); (L.C.A.); (I.S.); (M.T.); (B.H.); (M.R.M.)
- Division 1.5 Protein Analysis, Federal Institute for Materials Research and Testing (BAM), Richard-Willstätter-Str. 11, 12489 Berlin, Germany
- Department of Chemistry, Humboldt-Universität zu Berlin, Brook-Taylor-Str. 2, 12489 Berlin, Germany
| | - Jing Zhao
- Department of Radiology, Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Charitéplatz 1, 10117 Berlin, Germany; (J.B.); (J.O.K.); (J.Z.); (D.B.M.); (J.M.); (L.C.A.); (I.S.); (M.T.); (B.H.); (M.R.M.)
| | - Dilyana B. Mangarova
- Department of Radiology, Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Charitéplatz 1, 10117 Berlin, Germany; (J.B.); (J.O.K.); (J.Z.); (D.B.M.); (J.M.); (L.C.A.); (I.S.); (M.T.); (B.H.); (M.R.M.)
- Department of Veterinary Medicine, Institute of Veterinary Pathology, Freie Universität Berlin, Robert-von-Ostertag-Str. 15, Building 12, 14163 Berlin, Germany
| | - Jana Moeckel
- Department of Radiology, Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Charitéplatz 1, 10117 Berlin, Germany; (J.B.); (J.O.K.); (J.Z.); (D.B.M.); (J.M.); (L.C.A.); (I.S.); (M.T.); (B.H.); (M.R.M.)
| | - Lisa C. Adams
- Department of Radiology, Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Charitéplatz 1, 10117 Berlin, Germany; (J.B.); (J.O.K.); (J.Z.); (D.B.M.); (J.M.); (L.C.A.); (I.S.); (M.T.); (B.H.); (M.R.M.)
| | - Ingolf Sack
- Department of Radiology, Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Charitéplatz 1, 10117 Berlin, Germany; (J.B.); (J.O.K.); (J.Z.); (D.B.M.); (J.M.); (L.C.A.); (I.S.); (M.T.); (B.H.); (M.R.M.)
| | - Matthias Taupitz
- Department of Radiology, Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Charitéplatz 1, 10117 Berlin, Germany; (J.B.); (J.O.K.); (J.Z.); (D.B.M.); (J.M.); (L.C.A.); (I.S.); (M.T.); (B.H.); (M.R.M.)
| | - Bernd Hamm
- Department of Radiology, Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Charitéplatz 1, 10117 Berlin, Germany; (J.B.); (J.O.K.); (J.Z.); (D.B.M.); (J.M.); (L.C.A.); (I.S.); (M.T.); (B.H.); (M.R.M.)
| | - Marcus R. Makowski
- Department of Radiology, Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Charitéplatz 1, 10117 Berlin, Germany; (J.B.); (J.O.K.); (J.Z.); (D.B.M.); (J.M.); (L.C.A.); (I.S.); (M.T.); (B.H.); (M.R.M.)
- School of Biomedical Engineering and Imaging Sciences, King’s College London, St Thomas’ Hospital Westminster Bridge Road, London SE1 7EH, UK
- Department of Diagnostic and Interventional Radiology, School of Medicine & Klinikum Rechts der Isar, Technical University of Munich, Munich (TUM), Ismaninger Str. 22, 81675 München, Germany
| |
Collapse
|
43
|
Schieda N, van der Pol CB, Walker D, Tsampalieros AK, Maralani PJ, Woo S, Davenport MS. Adverse Events to the Gadolinium-based Contrast Agent Gadoxetic Acid: Systematic Review and Meta-Analysis. Radiology 2020; 297:565-572. [DOI: 10.1148/radiol.2020200073] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
|
44
|
Stingeni L, Bianchi L, Tramontana M, Pigatto PD, Patruno C, Corazza M, Foti C, Fabbrocini G, Micali G, Romita P, Napolitano M, Hansel K. Skin tests in the diagnosis of adverse drug reactions. GIORN ITAL DERMAT V 2020; 155:602-621. [DOI: 10.23736/s0392-0488.20.06698-5] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
|
45
|
Ward R, Purysko AS. Round table: arguments against using multiparametric prostate MRI protocols. Abdom Radiol (NY) 2020; 45:3997-4002. [PMID: 32140766 DOI: 10.1007/s00261-020-02456-z] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Biparametric MRI (bpMRI), which uses only T2-weighted imaging and diffusion-weighted imaging, continues to gain support for the detection of prostate cancer, as this imaging technique offers many benefits over traditional mpMRI. However, the Prostate Imaging Reporting and Data System (PI-RADS) v2.1 document released in 2019 emphasized that mpMRI is still preferred over bpMRI in most clinical scenarios. As one article in a series of four providing arguments for and against using mpMRI and bpMRI protocols, this paper provides arguments against using mpMRI. Within this article, we discuss recent data suggesting equivalent performance between bpMRI and mpMRI in the detection of prostate cancer. The limited utility of dynamic contrast enhancement in the evaluation of prostate cancer according to the PI-RADS v2.1 document is also reviewed. Finally, we detail the large financial and time costs, legal and logistical issues, and potential for patient harm that must be considered with the administration of contrast.
Collapse
|
46
|
Hypersensitivity to gadolinium-based contrast agents: A single-center retrospective analysis over 7 years. THE JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE 2020; 9:1746-1749.e2. [PMID: 33248281 DOI: 10.1016/j.jaip.2020.11.023] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Subscribe] [Scholar Register] [Received: 05/09/2020] [Revised: 11/06/2020] [Accepted: 11/09/2020] [Indexed: 11/23/2022]
|
47
|
Nong Q, Chen X, Hu L, Huang Y, Luan T, Liu H, Chen B. Identification and characterization of Gd-binding proteins in NIH-3T3 cells. Talanta 2020; 219:121281. [DOI: 10.1016/j.talanta.2020.121281] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2020] [Revised: 06/03/2020] [Accepted: 06/06/2020] [Indexed: 11/30/2022]
|
48
|
Comparison of diagnostic accuracy between [ 18F]FDG PET/MRI and contrast-enhanced MRI in T staging for oral tongue cancer. Ann Nucl Med 2020; 34:952-959. [PMID: 33040312 DOI: 10.1007/s12149-020-01526-y] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2020] [Accepted: 09/09/2020] [Indexed: 12/24/2022]
Abstract
OBJECTIVE Integrated PET/MRI with [18F]FDG is advantageous in that it enables simultaneous PET and MR imaging with higher soft-tissue contrast, multiplanar image acquisition, and functional imaging capability without using fat suppression and gadolinium-based contrast agents (GBCAs). The aims of this study were to demonstrate the feasibility of [18F]FDG PET/MRI for assessing the extent of the primary tumor (T) in oral tongue cancer (OTC) based on the 8th edition of American Joint Committee on Cancer (AJCC) cancer staging system, and to compare the diagnostic accuracy between [18F]FDG PET/MRI and contrast-enhanced MRI (ceMRI). METHODS 18 patients with biopsy-proven operable OTC underwent preoperative regional [18F]FDG PET/MRI and ceMRI within 2 weeks. For [18F]FDG PET/MRI, rainbow-colored PET images were overlaid on the corresponding MR images. Tumor size and the depth of invasion (DOI) were visually measured on [18F]FDG PET/MRI and ceMRI. The size, DOI, and clinical T stage were evaluated using the final surgical pathology as the reference. RESULTS Of the 18 OTCs, one was not detected by ceMRI due to metal artifacts from an artificial denture, and another due to superficial type (pathological DOI = 0 mm). Tumor sizes measured by ceMRI and [18F]FDG PET/MRI had significant positive correlations with the pathological size (r = 0.80 and r = 0.90, respectively), and DOIs measured by ceMRI and [18F]FDG PET/MRI had significant positive correlations with the pathological DOI (r = 0.74 and r = 0.64, respectively). The means ± SD of size (mm) were 20.4 ± 9.1, 22.9 ± 10.9, and 26.2 ± 10.0, and those of DOI (mm) were 7.1 ± 2.5, 6.9 ± 2.2, and 5.8 ± 3.2 for ceMRI, [18F]FDG PET/MRI, and pathology, respectively. A significant difference was observed in tumor size between ceMRI and pathology (p < 0.05), whereas no significant differences were observed between any other sizes, DOIs, or T stages. The accuracy for T status was 72% (13/18 including 2 undetectable cases) for ceMRI and 89% (16/18) for [18F]FDG PET/MRI. CONCLUSIONS Although shallow DOIs are often overestimated, regional [18F]FDG PET/MRI without fat suppression and gadolinium enhancement is comparable to and may be substituted for ceMRI in preoperative T staging for OTC patients, reducing metal artifacts and avoiding the adverse effects of GBCAs.
Collapse
|
49
|
Khalighinejad P, Parrott D, Sherry AD. Imaging Tissue Physiology In Vivo by Use of Metal Ion-Responsive MRI Contrast Agents. Pharmaceuticals (Basel) 2020; 13:E268. [PMID: 32987721 PMCID: PMC7598704 DOI: 10.3390/ph13100268] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2020] [Revised: 09/21/2020] [Accepted: 09/22/2020] [Indexed: 12/18/2022] Open
Abstract
Paramagnetic metal ion complexes, mostly based on gadolinium (Gd3+), have been used for over 30 years as magnetic resonance imaging (MRI) contrast agents. Gd3+-based contrast agents have a strong influence on T1 relaxation times and are consequently the most commonly used agents in both the clinical and research environments. Zinc is an essential element involved with over 3000 different cellular proteins, and disturbances in tissue levels of zinc have been linked to a wide range of pathologies, including Alzheimer's disease, prostate cancer, and diabetes mellitus. MR contrast agents that respond to the presence of Zn2+ in vivo offer the possibility of imaging changes in Zn2+ levels in real-time with the superior spatial resolution offered by MRI. Such responsive agents, often referred to as smart agents, are typically composed of a paramagnetic metal ion with a ligand encapsulating it and one or more chelating units that selectively bind with the analyte of interest. Translation of these agents into clinical radiology is the next goal. In this review, we discuss Gd3+-based MR contrast agents that respond to a change in local Zn2+ concentration.
Collapse
Affiliation(s)
- Pooyan Khalighinejad
- Advanced Imaging Research Center, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA;
| | - Daniel Parrott
- Department of Radiology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA;
| | - A. Dean Sherry
- Advanced Imaging Research Center, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA;
- Department of Radiology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA;
- Department of Chemistry & Biochemistry, University of Texas at Dallas, Richardson, TX 75080, USA
| |
Collapse
|
50
|
Xiao B, Zhou X, Xu H, Zhang W, Xu X, Tian F, Qian Y, Yu F, Pu C, Hu H, Zhou Z, Liu X, Patra HK, Slater N, Tang J, Gao J, Shen Y. On/off switchable epicatechin-based ultra-sensitive MRI-visible nanotheranostics - see it and treat it. Biomater Sci 2020; 8:5210-5218. [PMID: 32844846 DOI: 10.1039/d0bm00842g] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
Nanotechnology has a remarkable impact on the preclinical development of future medicines. However, the complicated preparation and systemic toxicity to living systems prevent them from translation to clinical applications. In the present report, we developed a polyepicatechin-based on/off switchable ultra-sensitive magnetic resonance imaging (MRI) visible theranostic nanoparticle (PEMN) for image-guided photothermal therapy (PTT) using our strategy of integrating polymerization and biomineralization into the protein template. We have exploited natural polyphenols as the near infra-red (NIR) switchable photothermal source and MnO2 for the MRI-guided theranostics. PEMN demonstrates excellent MRI contrast ability with a longitudinal relaxivity value up to 30.01 mM-1 s-1. PEMN has shown great tumor inhibition on orthotopic breast tumors and the treatment could be made switchable with an on/off interchangeable mode as needed. PEMN was found to be excretable mainly through the kidneys, avoiding potential systemic toxicity. Thus, PEMN could be extremely useful for developing on-demand therapeutics via'see it and treat it' means with distinguished MRI capability and on/off switchable photothermal properties.
Collapse
Affiliation(s)
- Bing Xiao
- Key Laboratory of Biomass Chemical Engineering of Ministry of Education, Center for Bionanoengineering, and College of Chemical and Biological Engineering, Zhejiang University, Hangzhou, Zhejiang 310027, China.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|